Page last updated: 2024-10-23

aspirin and Nasal Catarrh

aspirin has been researched along with Nasal Catarrh in 205 studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Research Excerpts

ExcerptRelevanceReference
"Aspirin-induced chronic rhinosinusitis (CRS) is a severe progressive persistent disease, usually associated with nasal polyps (NPs)."9.30Efficacy of hypertonic (2.3%) sea water in patients with aspirin-induced chronic rhinosinusitis following endoscopic sinus surgery. ( Barać, A; Gaćeša, D; Jožin, SM; Kovačević, SV; Perić, A; Perić, AV, 2019)
"Numerous open trials have demonstrated the beneficial clinical effects of aspirin desensitization (AD) in patients with aspirin-induced asthma (AIA)."9.19Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study. ( Bochenek, G; Ćmiel, A; Gielicz, A; Niżankowska-Mogilnicka, E; Plutecka, H; Sanak, M; Stręk, P; Świerczyńska-Krępa, M; Szczeklik, A, 2014)
"Aspirin-exacerbated respiratory disease (AERD) is characterized by the clinical triad of chronic rhinosinusitis with nasal polyps, asthma, and an intolerance to medications that inhibit the cycloxgenase-1 enzyme."9.12The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, ( Baptist, AP; Borish, L; Bosso, JV; Buchheit, KM; Cahill, KN; Campo, P; Cho, SH; Jerschow, E; Keswani, A; Laidlaw, TM; Levy, JM; Nanda, A; Stevens, WW; White, AA, 2021)
"The aim of this study was to assess the efficacy of leucotrien- antagonists in aspirin-intolerant asthma (AIA)."9.10[The effectiveness of leukotriene antagonists in the treatment of aspirin-intolerant asthmatic patients]. ( Arvin-Berod, C; Paganin, F; Poubeau, P; Yvin, JL, 2003)
"Aspirin-induced asthma/rhinitis (AIAR) is characterized by the altered metabolism of leukotrienes and proinflammatory prostaglandins."9.10Nasal versus bronchial and nasal response to oral aspirin challenge: Clinical and biochemical differences between patients with aspirin-induced asthma/rhinitis. ( Gielicz, A; Nizankowska-Mogilnicka, E; Swierczynska, M; Szczeklik, A; Zarychta, J, 2003)
"We performed a double-blind, crossover, placebo-controlled study on the effect of fluticasone propionate (FP) treatment on chronic eosinophilic rhinosinusitis in 15 patients with aspirin-induced asthma (AIA)."9.08Intranasal fluticasone propionate for chronic eosinophilic rhinitis in patients with aspirin-induced asthma. ( Duplaga, M; Mastalerz, L; Milewski, M; Nizankowska, E; Szczeklik, A, 1997)
"Aspirin-Exacerbated Respiratory Disease (AERD) and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) are both characterized by the presence of chronic sinonasal inflammation and nasal polyps."8.93Aspirin-Exacerbated Respiratory Disease as an Endotype of Chronic Rhinosinusitis. ( Schleimer, RP; Stevens, WW, 2016)
"Aspirin-exacerbated respiratory disease (AERD) is a clinical condition which results in adverse upper and lower respiratory symptoms, particularly rhinitis, conjunctivitis, bronchospasm, and/or laryngospasm, following exposure to cyclooxygenase-1 (COX-1) inhibiting drugs, namely aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs)."8.91Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD). ( Dazy, KM; Simon, RA; Waldram, JD, 2015)
"Chronic rhinosinusitis patients with nasal polyps can be aspirin sensitive or aspirin tolerant."8.90Topical nasal lysine aspirin in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis with nasal polyposis. ( Parikh, A; Scadding, GK, 2014)
"Chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma frequently coexist and are always present in patients with aspirin exacerbated respiratory disease (AERD)."8.90Prostaglandin E2 receptors in asthma and in chronic rhinosinusitis/nasal polyps with and without aspirin hypersensitivity. ( Machado-Carvalho, L; Picado, C; Roca-Ferrer, J, 2014)
"The presence of aspirin-exacerbated respiratory disease (AERD) in a patient with chronic rhinosinusitis with nasal polyps and asthma is associated with severe eosinophilic upper and lower airway disease."8.89Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease. ( Mullol, J; Picado, C, 2013)
"This review is set to revisit the pathogenesis of aspirin-exacerbated respiratory disease (AERD), the diagnostic method used, and finally the real impact of aspirin desensitization on chronic sinusitis with nasal polyposis (CRSwNP) in aspirin intolerant patients."8.87Role of aspirin desensitization in the management of chronic rhinosinusitis. ( Rizk, H, 2011)
"The purpose of this review is to highlight recent advances in gene-expression profiling of nasal polyps in patients with chronic rhinosinusitis and aspirin-sensitive asthma."8.85Gene-expression signatures of nasal polyps associated with chronic rhinosinusitis and aspirin-sensitive asthma. ( Metson, R; Platt, M; Stankovic, K, 2009)
"Aspirin-exacerbated respiratory disease (AERD) is a chronic inflammatory disease characterized by chronic rhinosinusitis, nasal polyposis, asthma, and airway reactivity to aspirin and other nonsteroidal antiinflammatory drugs (NSAIDs)."8.84The clinical effectiveness of aspirin desensitization in chronic rhinosinusitis. ( Williams, AN; Woessner, KM, 2008)
"To provide a diagnostic strategy for evaluating and treating patients with aspirin sensitivity, with additional consideration for issues specific to patients with coronary artery disease (CAD)."8.82Aspirin sensitivity: implications for patients with coronary artery disease. ( Gollapudi, RR; Simon, RA; Stevenson, DD; Teirstein, PS, 2004)
"Interesting findings relating to aspirin-induced asthma recently emerged."8.81Aspirin-induced rhinitis and asthma. ( Nizankowska, E; Sanak, M; Swierczynska, M; Szczeklik, A, 2001)
"Patients with asthma and nasal polyps have been warned to avoid aspirin because of a tendency to develop hypersensitivity reactions."8.77Desensitization to aspirin in aspirin-sensitive patients with rhino-sinusitis and asthma: a review. ( Knight, A, 1989)
" In our previous studies, we showed that the TNFA -308A allele is a genetic predisposition factor in a subgroup of aspirin-sensitive (ASA+) CRS patients suffering from nasal polyps (NP) in the Hungarian population."7.81A conserved linkage group on chromosome 6, the 8.1 ancestral haplotype, is a predisposing factor of chronic rhinosinusitis associated with nasal polyposis in aspirin-sensitive Hungarians. ( Bella, Z; Hirschberg, A; Kadocsa, E; Kemény, L; Kiricsi, Á; Polyánka, H; Révész, M; Szabó, K; Szabó, Z; Széll, M; Vóna, I, 2015)
"Chronic rhinosinusitis (CRS) with nasal polyposis (NP) may be associated with hypersensitivity to nonsteroidal anti-inflammatory drugs, representing a syndrome of aspirin-exacerbated respiratory disease (AERD)."7.78Incidence of aspirin hypersensitivity in patients with chronic rhinosinusitis and diagnostic value of urinary leukotriene E4. ( Celejewska-Wójcik, N; Cybulska, A; Hartwich, P; Hydzik-Sobocińska, K; Januszek, R; Mastalerz, L; Nieckarz, R; Oleś, K; Sanak, M; Stręk, P; Szaleniec, J; Wójcik, K, 2012)
"The present study inluded 22 patients presenting either with very severe or moderately severe aspirin triad 17 of whom suffered exacerbation of chronic polypous suppurative rhinosinusitis."7.77[The treatment of polypous suppurative rhinosinusitis in the patients presenting with the severe and moderate aspirin triad]. ( Riabova, MA; Shumilova, NA, 2011)
"Rhinosinusitis is highly associated with aspirin-intolerant asthma (AIA)."7.74Association between a TGFbeta1 promoter polymorphism and rhinosinusitis in aspirin-intolerant asthmatic patients. ( Holloway, JW; Kim, SH; Park, CS; Park, HS; Shin, HD, 2007)
"Cysteinyl leukotrienes play a disease-regulating role in rhinosinusitis and asthma, particularly aspirin-sensitive disease."7.73Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis. ( Corrigan, C; Lee, T; Mallett, K; Parikh, A; Roberts, D; Scadding, G; Ying, S, 2005)
"Hypersensitivity to aspirin usually takes the form of a clinical syndrome combining chronic rhinitis, nasal polyposis and asthma attacks that are exacerbated by aspirin or other non steroidal anti-inflammatory drugs (NSAIDs)."7.73[New pathophysiological concepts on aspirin hypersensitivity (Widal syndrome); diagnostic and therapeutic consequences]. ( de Weck, A; Gamboa, P; Sanz, ML, 2005)
"To address the hypothesis that expression of 1 or more EP receptors on nasal mucosal inflammatory cells is deficient in patients with aspirin-sensitive compared with nonaspirin-sensitive polypoid rhinosinusitis."7.73Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells. ( Corrigan, CJ; Lee, TH; Meng, Q; Parikh, A; Scadding, G; Ying, S, 2006)
" Urinary leukotriene E4 concentration (LTE4), that reflects the whole body production of cysteinil-leukotrienes, is particularly increased in patients with aspirin-intolerant asthma (AIA)."7.73Aspirin induced asthma (AIA) with nasal polyps has the highest basal LTE4 excretion: a study vs AIA without polyps, mild topic asthma, and normal controls. ( Dal Negro, RW; Facchini, FM; Micheletto, C; Tognella, S; Visconti, M, 2006)
"There were significant differences in the expression of COX and LO enzymes between patients with nasal polyps and controls, irrespective of aspirin sensitivity."7.73Expression of cyclooxygenase and lipoxygenase enzymes in nasal polyps of aspirin-sensitive and aspirin-tolerant patients. ( Kingdom, TT; Owens, JM; Shroyer, KR, 2006)
"Aspirin-sensitive rhinitis is the manifestation of aspirin intolerance in the upper respiratory tract."7.72Aspirin-sensitive rhinitis-associated changes in upper airway innervation. ( Cryer, A; Dinh, QT; Fischer, A; Groneberg, DA; Heppt, W; Peiser, C; Welker, P; Witt, C; Zweng, M, 2003)
"The urinary leukotriene E4 (U-LTE4) concentration is significantly increased in patients with aspirin-intolerant asthma (AIA)."7.72Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis. ( Akiyama, K; Higashi, A; Higashi, N; Ishii, T; Kawagishi, Y; Mita, H; Osame, M; Taniguchi, M, 2004)
"Nasal polyps were obtained from 16 aspirin-tolerant patients with asthma/rhinitis (ATAR) and 18 aspirin-intolerant patients with asthma/rhinitis (AIAR) undergoing nasal polypectomy."7.72Dynamics of COX-2 in nasal mucosa and nasal polyps from aspirin-tolerant and aspirin-intolerant patients with asthma. ( Alobid, I; Mullol, J; Picado, C; Pujols, L; Roca-Ferrer, J; Xaubet, A, 2004)
"Although many studies have assumed that the overproduction of cysteinyl- leukotrienes (cys-LTs) and an imbalance of arachidonic acid metabolism may be plausible causes for the pathogenesis of aspirin-intolerant asthma (AIA), there has been little experimental evidence to substantiate this notion in lower airways of patients with AIA."7.71A comparative study of eicosanoid concentrations in sputum and urine in patients with aspirin-intolerant asthma. ( Akiyama, K; Higashi, N; Mita, H; Osame, M; Taniguchi, M, 2002)
"Patients with aspirin-hypersensitive rhinosinusitis/asthma suffer from a severe form of hyperplastic rhinosinusitis with recurrent polyposis."7.71Decreased apoptosis and distinct profile of infiltrating cells in the nasal polyps of patients with aspirin hypersensitivity. ( Danilewicz, M; Grzegorczyk, J; Kornatowski, T; Kowalski, ML; Pawliczak, R; Wagrowska-Danilewicz, M, 2002)
"Nasal provocation tests with lysine-aspirin have recently been introduced for assessment of aspirin intolerant asthma."7.70Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: evaluation of nasal response by acoustic rhinometry. ( Casadevall, J; Mullol, J; Picado, C; Ventura, PJ, 2000)
"The high prevalence of aspirin intolerance in asthmatics and patients with nasal polyps as well as reports of familial clustering suggest a genetic disposition of this disease."7.70[Family study of patients with aspirin intolerance and rhinosinusitis]. ( Langenbeck, U; May, A; Wagner, D; Weber, A, 2000)
"Inhalation and nasal aspirin challenge has been investigated in asthma patients with co-existing rhinitis."7.68Inhalation and nasal challenge in the diagnosis of aspirin-induced asthma. ( Davies, BH; Pawlowicz, A; Williams, WR, 1991)
"One hundred seven known aspirin (ASA)-sensitive patients with rhinosinusitis-asthma were studied from 1975 to 1988."7.68Long-term effects of aspirin desensitization--treatment for aspirin-sensitive rhinosinusitis-asthma. ( Mathison, DA; Simon, RA; Stevenson, DD; Sweet, JM, 1990)
"Aspirin-sensitive asthma is not well documented in children."7.66Aspirin-induced asthma in children. ( Collins-Williams, C; Tan, Y, 1982)
"Eleven patients with asthma and aspirin hypersensitivity have been challenged with eight non-steroidal anti-inflammatory drugs."7.65Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. ( Czerniawska-Mysik, G; Gryglewski, RJ; Szczeklik, A, 1975)
"Bronchial asthma is not a homogenous disease."6.41Diagnosis, prevention and treatment of aspirin-induced asthma and rhinitis. ( Bánska, K; Bochenek, G; Nizankowska, E; Szabó, Z; Szczeklik, A, 2002)
"Treatment of the nasal polyps has been shown to improve the patients' asthma."6.38Nasal polyps, bronchial asthma and aspirin sensitivity. ( Hawke, M; Jeney, E; Probst, L; Stoney, P, 1992)
"Aspirin sensitivity has a highly significant association with AFRS."5.48Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study. ( Ahmed, S; Almeyda, R; Anari, S; Carrie, S; Cathcart, R; Clark, A; Coombes, E; Erskine, S; Farboud, A; Hobson, J; Hopkins, C; Jervis, P; Kara, N; Khalil, H; Kumar, N; Mansell, N; Panesaar, J; Philpott, C; Philpott, CM; Prinsley, P; Ray, J; Robertson, A; Salam, M; Sunkaraneni, S; Sunkaraneni, V; Wilson, A; Woods, J, 2018)
"Aspirin-exacerbated respiratory disease (AERD) is characterized by abnormal arachidonic acid metabolism leading to chronic rhinosinusitis with nasal polyposis (CRSwNP), asthma, and upper and/or lower respiratory symptoms after ingestion of cyclooxygenase-1 inhibiting nonsteroidal antiinflammatory drugs."5.41Aspirin-Exacerbated Respiratory Disease and the Unified Airway: A Contemporary Review. ( Choby, G; Divekar, RD; Hagan, JB; O'Brien, EK; Pinheiro-Neto, CD; Stokken, JK; Walters, BK; Willson, TJ, 2023)
"Aspirin-exacerbated respiratory disease (AERD) is a chronic respiratory condition characterized by severe chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic asthma, and respiratory reactions to cyclooxygenase inhibitors."5.41Aspirin-exacerbated respiratory disease: Updates in the era of biologics. ( Buchheit, KM; Mullur, J, 2023)
"These post hoc analyses of pooled data from 2 BREATH phase 3 clinical trials, studies 1 and 2 (NCT01287039 and NCT01285323), examined asthma-related outcomes in patients with comorbid, self-reported CRSwNP with and without aspirin sensitivity."5.30Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps. ( Bardin, P; Bateman, ED; Garin, M; Germinaro, M; Hoyte, FCL; Katial, RK; Korn, S; McDonald, M; Weinstein, SF, 2019)
"Aspirin-induced chronic rhinosinusitis (CRS) is a severe progressive persistent disease, usually associated with nasal polyps (NPs)."5.30Efficacy of hypertonic (2.3%) sea water in patients with aspirin-induced chronic rhinosinusitis following endoscopic sinus surgery. ( Barać, A; Gaćeša, D; Jožin, SM; Kovačević, SV; Perić, A; Perić, AV, 2019)
"Tissue eosinophilia is regulated by chemical attractants and activating substances of various origins and plays a major part in the chronic inflammatory state."5.28Nonallergic rhinitis with eosinophilia syndrome a precursor of the triad: nasal polyposis, intrinsic asthma, and intolerance to aspirin. ( Guyot, JL; Hsieh, V; Maria, Y; Moneret-Vautrin, DA; Mouton, C; Wayoff, M, 1990)
"Aspirin exacerbated respiratory disease (AERD) is comprised of aspirin/acetylsalicylic acid (ASA) sensitivity, bronchial asthma, and nasal polyposis."5.20Treatment of aspirin exacerbated respiratory disease with a low salicylate diet: a pilot crossover study. ( Au, M; Gupta, MK; Hoffbauer, S; Nayan, S; Sommer, DD; Sowerby, LJ, 2015)
"Numerous open trials have demonstrated the beneficial clinical effects of aspirin desensitization (AD) in patients with aspirin-induced asthma (AIA)."5.19Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study. ( Bochenek, G; Ćmiel, A; Gielicz, A; Niżankowska-Mogilnicka, E; Plutecka, H; Sanak, M; Stręk, P; Świerczyńska-Krępa, M; Szczeklik, A, 2014)
"To determine acute analgesia by acetylsalicylic acid (ASA) when combined with pseudoephedrine (PSE) in patients with upper respiratory tract infection (URTI), we used the sore throat pain model to measure single-dose effects of ASA 500 mg/PSE 30 mg, ASA 1000 mg/PSE 60 mg, and acetaminophen (APAP) 1000 mg/PSE 60 mg (serving as a positive control)."5.14Demonstration of the analgesic efficacy and dose-response of acetylsalicylic acid with pseudoephedrine. ( Becka, M; Bey, M; Gagney, D; Sanner, KM; Schachtel, BP; Schachtel, EJ; Voelker, M, 2010)
"Aspirin-exacerbated respiratory disease (AERD) is characterized by the clinical triad of chronic rhinosinusitis with nasal polyps, asthma, and an intolerance to medications that inhibit the cycloxgenase-1 enzyme."5.12The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, ( Baptist, AP; Borish, L; Bosso, JV; Buchheit, KM; Cahill, KN; Campo, P; Cho, SH; Jerschow, E; Keswani, A; Laidlaw, TM; Levy, JM; Nanda, A; Stevens, WW; White, AA, 2021)
"The aim of this study was to assess the efficacy of leucotrien- antagonists in aspirin-intolerant asthma (AIA)."5.10[The effectiveness of leukotriene antagonists in the treatment of aspirin-intolerant asthmatic patients]. ( Arvin-Berod, C; Paganin, F; Poubeau, P; Yvin, JL, 2003)
"Aspirin-induced asthma/rhinitis (AIAR) is characterized by the altered metabolism of leukotrienes and proinflammatory prostaglandins."5.10Nasal versus bronchial and nasal response to oral aspirin challenge: Clinical and biochemical differences between patients with aspirin-induced asthma/rhinitis. ( Gielicz, A; Nizankowska-Mogilnicka, E; Swierczynska, M; Szczeklik, A; Zarychta, J, 2003)
"We performed a double-blind, crossover, placebo-controlled study on the effect of fluticasone propionate (FP) treatment on chronic eosinophilic rhinosinusitis in 15 patients with aspirin-induced asthma (AIA)."5.08Intranasal fluticasone propionate for chronic eosinophilic rhinitis in patients with aspirin-induced asthma. ( Duplaga, M; Mastalerz, L; Milewski, M; Nizankowska, E; Szczeklik, A, 1997)
"Aspirin-exacerbated respiratory disease (AERD) represents an aggressive form of chronic rhinosinusitis with nasal polyposis that is notoriously challenging to treat."5.05Aspirin desensitization therapy in aspirin-exacerbated respiratory disease: a systematic review. ( Chin, CJ; Larivée, N, 2020)
"Aspirin-exacerbated respiratory disease is a chronic and treatment-resistant disease, characterized by the presence of eosinophilic rhinosinusitis, nasal polyposis, bronchial asthma, and nonsteroidal anti-inflammatory drugs hypersensitivity."4.98Aspirin exacerbated respiratory disease: Current topics and trends. ( Guaní-Guerra, E; Moreno-Paz, FJ; Rodríguez-Jiménez, JC; Terán, LM, 2018)
"Aspirin-exacerbated respiratory disease (AERD) refers to the combination of asthma, chronic rhinosinusitis with nasal polyposis, and acute upper and lower respiratory tract reactions to the ingestion of aspirin (acetylsalicylic acid, ASA) and other cyclooxygenase-1 inhibiting non-steroidal anti-inflammatory drugs."4.95Aspirin-exacerbated respiratory disease and current treatment modalities. ( Cingi, C; Kar, M; Muluk, NB; Sakalar, EG, 2017)
"Aspirin-exacerbated respiratory disease (AERD) represents a severe form of chronic rhinosinusitis (CRS) characterized by nasal polyposis, bronchial asthma, and aspirin intolerance."4.93The Role of Surgery in Management of Samter's Triad: A Systematic Review. ( Adelman, J; Krouse, JH; McLean, C; Shaigany, K, 2016)
"Aspirin-Exacerbated Respiratory Disease (AERD) and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) are both characterized by the presence of chronic sinonasal inflammation and nasal polyps."4.93Aspirin-Exacerbated Respiratory Disease as an Endotype of Chronic Rhinosinusitis. ( Schleimer, RP; Stevens, WW, 2016)
"Aspirin-exacerbated respiratory disease is defined by the clinical tetrad of aspirin sensitivity, nasal polyps, asthma, and chronic rhinosinusitis."4.93Current complications and treatment of aspirin-exacerbated respiratory disease. ( Cook, KA; Stevenson, DD, 2016)
"Aspirin-exacerbated respiratory disease (AERD) is a clinical condition which results in adverse upper and lower respiratory symptoms, particularly rhinitis, conjunctivitis, bronchospasm, and/or laryngospasm, following exposure to cyclooxygenase-1 (COX-1) inhibiting drugs, namely aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs)."4.91Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD). ( Dazy, KM; Simon, RA; Waldram, JD, 2015)
"Aspirin-exacerbated respiratory disease is a clinical entity comprising chronic rhinosinusitis with nasal polyposis, asthma and intolerance to COX-1 inhibiting drugs."4.91Aspirin-exacerbated respiratory disease: characteristics and management strategies. ( Dazy, KM; Simon, RA; Waldram, JD, 2015)
"Hypersensitivity to acetylsalicylic acid (ASA) is characterized by the co-occurrence of symptoms so-called aspirin triad, which include bronchial asthma, chronic rhinitis and sinusitis and the nasal mucosa polyps."4.91[Hypersensitivity to acetylsalicylic acid]. ( Skrętkowicz, J; Wojtczak, A, 2015)
" Several clinical phenotypes often leading to uncontrolled disease, including adult nasal polyposis, aspirin-exacerbated respiratory disease, and allergic fungal rhinosinusitis, are characterized by a common endotype: a TH2 bias is associated with a higher likelihood of comorbid asthma and recurrence after surgical treatment."4.91Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis. ( Bachert, C; Gevaert, P; Zhang, L, 2015)
"Chronic rhinosinusitis patients with nasal polyps can be aspirin sensitive or aspirin tolerant."4.90Topical nasal lysine aspirin in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis with nasal polyposis. ( Parikh, A; Scadding, GK, 2014)
"Chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma frequently coexist and are always present in patients with aspirin exacerbated respiratory disease (AERD)."4.90Prostaglandin E2 receptors in asthma and in chronic rhinosinusitis/nasal polyps with and without aspirin hypersensitivity. ( Machado-Carvalho, L; Picado, C; Roca-Ferrer, J, 2014)
"The presence of aspirin-exacerbated respiratory disease (AERD) in a patient with chronic rhinosinusitis with nasal polyps and asthma is associated with severe eosinophilic upper and lower airway disease."4.89Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease. ( Mullol, J; Picado, C, 2013)
"This review is set to revisit the pathogenesis of aspirin-exacerbated respiratory disease (AERD), the diagnostic method used, and finally the real impact of aspirin desensitization on chronic sinusitis with nasal polyposis (CRSwNP) in aspirin intolerant patients."4.87Role of aspirin desensitization in the management of chronic rhinosinusitis. ( Rizk, H, 2011)
"The purpose of this review is to highlight recent advances in gene-expression profiling of nasal polyps in patients with chronic rhinosinusitis and aspirin-sensitive asthma."4.85Gene-expression signatures of nasal polyps associated with chronic rhinosinusitis and aspirin-sensitive asthma. ( Metson, R; Platt, M; Stankovic, K, 2009)
"Aspirin-exacerbated respiratory disease (AERD) is a chronic inflammatory disease characterized by chronic rhinosinusitis, nasal polyposis, asthma, and airway reactivity to aspirin and other nonsteroidal antiinflammatory drugs (NSAIDs)."4.84The clinical effectiveness of aspirin desensitization in chronic rhinosinusitis. ( Williams, AN; Woessner, KM, 2008)
"In up to 10% of patients with bronchial asthma, aspirin and other nonsteroidal antiinflammatory drugs precipitate asthmatic attacks."4.82Aspirin intolerance and the cyclooxygenase-leukotriene pathways. ( Kiełbasa, B; Nizankowska-Mogilnicka, E; Sanak, M; Szczeklik, A, 2004)
"To provide a diagnostic strategy for evaluating and treating patients with aspirin sensitivity, with additional consideration for issues specific to patients with coronary artery disease (CAD)."4.82Aspirin sensitivity: implications for patients with coronary artery disease. ( Gollapudi, RR; Simon, RA; Stevenson, DD; Teirstein, PS, 2004)
" However, recently there has been some progress in elucidating the etiology of nasal polyposis, especially regarding tissue eosinophilia as well as the role of aspirin intolerance and eicosanoid mediators."4.82Current concepts in therapy of chronic rhinosinusitis and nasal polyposis. ( Gosepath, J; Mann, WJ, 2005)
"Chronic rhinosinusitis with nasal polyposis usually develops in aspirin-sensitive patients with asthma Arachidonic acid metabolism appears to be abnormal in the nasal polyps of aspirin-sensitive patients with asthma."4.81Aspirin intolerance and nasal polyposis. ( Picado, C, 2002)
"Relevant articles in the medical literature were derived from searching the MEDLINE database with key terms aspirin-sensitive asthma, cyclo-oxygenase enzymes 1 and 2."4.81Sensitivity to nonsteroidal anti-inflammatory drugs. ( Namazy, JA; Simon, RA, 2002)
"Interesting findings relating to aspirin-induced asthma recently emerged."4.81Aspirin-induced rhinitis and asthma. ( Nizankowska, E; Sanak, M; Swierczynska, M; Szczeklik, A, 2001)
"Patients with asthma and nasal polyps have been warned to avoid aspirin because of a tendency to develop hypersensitivity reactions."4.77Desensitization to aspirin in aspirin-sensitive patients with rhino-sinusitis and asthma: a review. ( Knight, A, 1989)
"Aspirin intolerance manifests itself as an acute urticaria-angioedema, bronchospasm, severe rhinitis, or shock occurring within three hours of aspirin ingestion."4.76Aspirin and allergic diseases: a review. ( Settipane, GA, 1983)
"Aspirin desensitization (AD) is effective in relieving asthma and sinonasal outcomes in patients with non-steroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD)."4.31Aspirin desensitization following endoscopic sinus surgery is effective in patients with nonsteroidal antiinflammatory drug exacerbated respiratory disease. ( Anadolu, Y; Atmiş, EÖ; Aydin, Ö; Çelik, GE; Yorulmaz, İ, 2023)
"These evidence-based guidelines support patients, clinicians, and other stakeholders in decisions about the use of intranasal corticosteroids (INCS), biologics, and aspirin therapy after desensitization (ATAD) for the management of chronic rhinosinusitis with nasal polyposis (CRSwNP)."4.31The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis. ( Bernstein, JA; Bognanni, A; Chu, DK; Ellis, AK; Golden, DBK; Greenhawt, M; Horner, CC; Ledford, DK; Lieberman, J; Luong, AU; Orlandi, RR; Oykhman, P; Peters, AT; Rank, MA; Samant, SA; Shaker, MS; Soler, ZM; Stevens, WW; Stukus, DR; Wang, J, 2023)
"A total of 30 patients with AERD, 30 chronic rhinosinusitis (CRS) with NP patients without aspirin sensitivity (CRSwNP), and 30 control subjects without inflammation of the nasal mucosa (C), selected for surgical treatment entered the study."4.31Inflammatory mediators in nasal secretions of patients with nasal polyposis with and without aspirin sensitivity. ( Cvetković, G; Gaćeša, D; Perić, A; Vojvodić, D, 2023)
"Aspirin-exacerbated respiratory disease (AERD) is a unique and often clinically severe disease affecting a subgroup of adults with asthma and chronic rhinosinusitis with nasal polyposis."4.31Mechanistic and clinical updates in AERD: 2021-2022. ( Cahill, KN; Stevens, WW, 2023)
" Quantitative and descriptive analyses of age, gender, nationality, presence of polyps, aspirin sensitivity, presence of urticaria, asthma, and allergies were performed."4.31Demographic and clinical profile of patients with chronic rhinosinusitis in Saudi Arabia. ( Alanazy, F; Alfallaj, R; Almousa, H; Aloulah, M; Alrasheed, A; Alromaih, S; Alroqi, AS; Alsaleh, S; Dousary, SA; Ismail, D; Mahjoub, S; Obaid, SB, 2023)
"Aspirin-exacerbated respiratory disease (AERD) consists of chronic rhinosinusitis with nasal polyps (CRSwNP), asthma, and hypersensitivity to aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs)."4.31Association Between Aspirin-Exacerbated Respiratory Disease and Atherosclerotic Cardiovascular Disease: A Retrospective Review of US Claims Data. ( Adame, MJ; Kuo, YF; Raji, M; Shan, Y; Tripple, JW; Zhang, Y, 2023)
"Nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD) asthma is characterized by chronic rhinosinusitis and intolerance of aspirin and other COX1 inhibitors."4.02Heterogeneity of lower airway inflammation in patients with NSAID-exacerbated respiratory disease. ( Bochenek, G; Gielicz, A; Jakiela, B; Plutecka, H; Przybyszowski, M; Rebane, A; Sladek, K; Soja, J, 2021)
"Aspirin-exacerbated respiratory disease (AERD) is a severe form of chronic rhinosinusitis with nasal polyps (CRSwNP) accompanied by asthma and an aspirin intolerance."3.96The time course of nasal cytokine secretion in patients with aspirin-exacerbated respiratory disease (AERD) undergoing aspirin desensitization: preliminary data. ( Eder, K; Gellrich, D; Gröger, M; Högerle, C; Pfrogner, E; San Nicoló, M, 2020)
"Aspirin-exacerbated respiratory disease (AERD) represents a severe endotype of chronic rhinosinusitis with nasal polyposis."3.96Surgical outcomes in aspirin-exacerbated respiratory disease without aspirin desensitization. ( Cottrell, J; Grose, E; Lee, DJ; Lee, JK; Lee, JM; Sykes, J; Yip, J, 2020)
"Background Aspirin-exacerbated respiratory disease (AERD), also known as Samter's triad or aspirin (ASA)-intolerant asthma, affects 7% of asthmatics and has a higher prevalence in those with chronic rhinosinusitis and concomitant nasal polyposis."3.88Long-term Clinical Outcomes of Aspirin Desensitization With Continuous Daily Aspirin Therapy in Aspirin-exacerbated Respiratory Disease. ( Waldram, JD; Walters, KM; White, AA; Woessner, KM, 2018)
"Oral aspirin challenge (OAC) reveals aspirin-exacerbated respiratory disease (AERD) in approximately 50% of unselected patients with chronic rhinosinusitis with nasal polyposis (CRSwNP)."3.85Olfaction and sinonasal symptoms in patients with CRSwNP and AERD and without AERD: a cross-sectional and longitudinal study. ( Gudziol, V; Hummel, T; Koschel, D; Michel, M; Sonnefeld, C, 2017)
" In our previous studies, we showed that the TNFA -308A allele is a genetic predisposition factor in a subgroup of aspirin-sensitive (ASA+) CRS patients suffering from nasal polyps (NP) in the Hungarian population."3.81A conserved linkage group on chromosome 6, the 8.1 ancestral haplotype, is a predisposing factor of chronic rhinosinusitis associated with nasal polyposis in aspirin-sensitive Hungarians. ( Bella, Z; Hirschberg, A; Kadocsa, E; Kemény, L; Kiricsi, Á; Polyánka, H; Révész, M; Szabó, K; Szabó, Z; Széll, M; Vóna, I, 2015)
"To demonstrate that quality-of-life outcomes after endoscopic sinus surgery are not compromised in patients with Samter's triad (asthma, nasal polyps, aspirin sensitivity) when compared to patients with eosinophilic chronic rhinosinusitis with nasal polyposis (eCRSwP) who are not aspirin sensitive."3.80Aspirin sensitivity does not compromise quality-of-life outcomes in patients with Samter's triad. ( Comer, BT; Jang, DW; Kountakis, SE; Lachanas, VA, 2014)
" The impact of surgery and factors such as the presence of polyps, asthma, and aspirin sensitivity on the bacterial state are poorly understood."3.79The bacteriology of chronic rhinosinusitis and the pre-eminence of Staphylococcus aureus in revision patients. ( Bassiouni, A; Cleland, EJ; Wormald, PJ, 2013)
"SPINK5 single-nucleotide polymorphisms (SNPs) and SPINK5 expression levels were correlated with CRS without (CRSsNP) and with nasal polyps (CRSwNP), aspirin intolerance, asthma, and allergies."3.78Low SPINK5 expression in chronic rhinosinusitis. ( Brieger, J; Fruth, K; Goebel, G; Gosepath, J; Koutsimpelas, D; Mann, WJ; Schmidtmann, I, 2012)
"Chronic rhinosinusitis (CRS) with nasal polyposis (NP) may be associated with hypersensitivity to nonsteroidal anti-inflammatory drugs, representing a syndrome of aspirin-exacerbated respiratory disease (AERD)."3.78Incidence of aspirin hypersensitivity in patients with chronic rhinosinusitis and diagnostic value of urinary leukotriene E4. ( Celejewska-Wójcik, N; Cybulska, A; Hartwich, P; Hydzik-Sobocińska, K; Januszek, R; Mastalerz, L; Nieckarz, R; Oleś, K; Sanak, M; Stręk, P; Szaleniec, J; Wójcik, K, 2012)
"The present study inluded 22 patients presenting either with very severe or moderately severe aspirin triad 17 of whom suffered exacerbation of chronic polypous suppurative rhinosinusitis."3.77[The treatment of polypous suppurative rhinosinusitis in the patients presenting with the severe and moderate aspirin triad]. ( Riabova, MA; Shumilova, NA, 2011)
"It was the aim of this study to investigate the prevalence of otologic manifestations in a cohort of Samter's syndrome patients (nasal polyps with chronic rhinosinusitis, aspirin intolerance and asthma)."3.75Otologic manifestations in Samter's syndrome. ( Caversaccio, M; Häusler, R; Helbling, A, 2009)
" In these cases, CRS tends to be associated with bronchial asthma (BA), especially, aspirin-intolerant asthma (AIA)."3.74Correlation between the prostaglandin D(2)/E(2) ratio in nasal polyps and the recalcitrant pathophysiology of chronic rhinosinusitis associated with bronchial asthma. ( Haruna, S; Moriyama, H; Otori, N; Yoshikawa, M; Yoshimura, T, 2008)
"Rhinosinusitis is highly associated with aspirin-intolerant asthma (AIA)."3.74Association between a TGFbeta1 promoter polymorphism and rhinosinusitis in aspirin-intolerant asthmatic patients. ( Holloway, JW; Kim, SH; Park, CS; Park, HS; Shin, HD, 2007)
"Aspirin desensitization is indicated for patients who have aspirin-exacerbated respiratory disease and whose asthma and/or rhinosinusitis is suboptimally controlled with inhaled corticosteroids and leukotriene-modifying drugs."3.74Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper. ( Bernstein, JA; Castells, MC; Gawchik, SM; Lee, TH; Macy, E; Settipane, RA; Simon, RA; Wald, J; Woessner, KM, 2007)
"We conducted a retrospective study to determine the prevalence of Samter's triad (nasal polyps, asthma, and aspirin sensitivity) in 208 consecutively presenting patients who had undergone functional endoscopic sinus surgery (FESS) for chronic rhinosinusitis from September 2001 through August 2003."3.74The prevalence of Samter's triad in patients undergoing functional endoscopic sinus surgery. ( Kim, JE; Kountakis, SE, 2007)
" Underlying conditions such as immune deficiency, Wegener's granulomatosis, Churg-Strauss syndrome, aspirin hypersensitivity and allergic fungal sinusitis may present as rhinosinusitis."3.74BSACI guidelines for the management of rhinosinusitis and nasal polyposis. ( Dixon, TA; Drake-Lee, AB; Durham, SR; Huber, PA; Jones, NS; Mirakian, R; Nasser, SM; Ryan, D; Scadding, GK, 2008)
"Cysteinyl leukotrienes play a disease-regulating role in rhinosinusitis and asthma, particularly aspirin-sensitive disease."3.73Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis. ( Corrigan, C; Lee, T; Mallett, K; Parikh, A; Roberts, D; Scadding, G; Ying, S, 2005)
"We have previously demonstrated that aspirin triggers specific generation of 15-hydroxyeicosateraenoic acid (15-HETE) from nasal polyp epithelial cells and peripheral blood leukocytes (PBL) from aspirin-sensitive (AS) but not aspirin-tolerant (AT) patients with asthma/rhinosinusitis."3.73Aspirin-triggered 15-HETE generation in peripheral blood leukocytes is a specific and sensitive Aspirin-Sensitive Patients Identification Test (ASPITest). ( Bienkiewicz, B; Cieslak, M; Dubuske, L; Grzegorczyk, J; Jedrzejczak, M; Kowalski, ML; Pawliczak, R; Ptasinska, A, 2005)
"Hypersensitivity to aspirin usually takes the form of a clinical syndrome combining chronic rhinitis, nasal polyposis and asthma attacks that are exacerbated by aspirin or other non steroidal anti-inflammatory drugs (NSAIDs)."3.73[New pathophysiological concepts on aspirin hypersensitivity (Widal syndrome); diagnostic and therapeutic consequences]. ( de Weck, A; Gamboa, P; Sanz, ML, 2005)
"To address the hypothesis that expression of 1 or more EP receptors on nasal mucosal inflammatory cells is deficient in patients with aspirin-sensitive compared with nonaspirin-sensitive polypoid rhinosinusitis."3.73Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells. ( Corrigan, CJ; Lee, TH; Meng, Q; Parikh, A; Scadding, G; Ying, S, 2006)
" Urinary leukotriene E4 concentration (LTE4), that reflects the whole body production of cysteinil-leukotrienes, is particularly increased in patients with aspirin-intolerant asthma (AIA)."3.73Aspirin induced asthma (AIA) with nasal polyps has the highest basal LTE4 excretion: a study vs AIA without polyps, mild topic asthma, and normal controls. ( Dal Negro, RW; Facchini, FM; Micheletto, C; Tognella, S; Visconti, M, 2006)
"There were significant differences in the expression of COX and LO enzymes between patients with nasal polyps and controls, irrespective of aspirin sensitivity."3.73Expression of cyclooxygenase and lipoxygenase enzymes in nasal polyps of aspirin-sensitive and aspirin-tolerant patients. ( Kingdom, TT; Owens, JM; Shroyer, KR, 2006)
"Aspirin-sensitive rhinitis is the manifestation of aspirin intolerance in the upper respiratory tract."3.72Aspirin-sensitive rhinitis-associated changes in upper airway innervation. ( Cryer, A; Dinh, QT; Fischer, A; Groneberg, DA; Heppt, W; Peiser, C; Welker, P; Witt, C; Zweng, M, 2003)
"The urinary leukotriene E4 (U-LTE4) concentration is significantly increased in patients with aspirin-intolerant asthma (AIA)."3.72Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis. ( Akiyama, K; Higashi, A; Higashi, N; Ishii, T; Kawagishi, Y; Mita, H; Osame, M; Taniguchi, M, 2004)
"Nasal polyps were obtained from 16 aspirin-tolerant patients with asthma/rhinitis (ATAR) and 18 aspirin-intolerant patients with asthma/rhinitis (AIAR) undergoing nasal polypectomy."3.72Dynamics of COX-2 in nasal mucosa and nasal polyps from aspirin-tolerant and aspirin-intolerant patients with asthma. ( Alobid, I; Mullol, J; Picado, C; Pujols, L; Roca-Ferrer, J; Xaubet, A, 2004)
"Although many studies have assumed that the overproduction of cysteinyl- leukotrienes (cys-LTs) and an imbalance of arachidonic acid metabolism may be plausible causes for the pathogenesis of aspirin-intolerant asthma (AIA), there has been little experimental evidence to substantiate this notion in lower airways of patients with AIA."3.71A comparative study of eicosanoid concentrations in sputum and urine in patients with aspirin-intolerant asthma. ( Akiyama, K; Higashi, N; Mita, H; Osame, M; Taniguchi, M, 2002)
"Aspirin-exacerbated respiratory disease (AERD) is a clinical syndrome characterized by chronic rhinitis, nasal polyps, asthma, and precipitation of asthma and rhinitis attacks after ingestion of aspirin (ASA) and most nonsteroidal anti-inflammatory drugs (NSAIDs)."3.71The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. ( Berges-Gimeno, MP; Simon, RA; Stevenson, DD, 2002)
"Patients with aspirin-sensitive rhinosinusitis, which is frequently associated with intrinsic bronchial asthma, can be desensitized by long-term treatment with oral aspirin."3.71Individual monitoring of aspirin desensitization. ( Amedee, RG; Gosepath, J; Mann, WJ; Schaefer, D, 2001)
"Patients with aspirin-hypersensitive rhinosinusitis/asthma suffer from a severe form of hyperplastic rhinosinusitis with recurrent polyposis."3.71Decreased apoptosis and distinct profile of infiltrating cells in the nasal polyps of patients with aspirin hypersensitivity. ( Danilewicz, M; Grzegorczyk, J; Kornatowski, T; Kowalski, ML; Pawliczak, R; Wagrowska-Danilewicz, M, 2002)
"Between 8-20 percent of adult asthmatics experience bronchospasm following ingestion of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs)."3.70NSAID-induced bronchospasm--a common and serious problem. A report from MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority. ( Sturtevant, J, 1999)
"Nasal provocation tests with lysine-aspirin have recently been introduced for assessment of aspirin intolerant asthma."3.70Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: evaluation of nasal response by acoustic rhinometry. ( Casadevall, J; Mullol, J; Picado, C; Ventura, PJ, 2000)
"The high prevalence of aspirin intolerance in asthmatics and patients with nasal polyps as well as reports of familial clustering suggest a genetic disposition of this disease."3.70[Family study of patients with aspirin intolerance and rhinosinusitis]. ( Langenbeck, U; May, A; Wagner, D; Weber, A, 2000)
" ASA challenges were performed in 17 ASA-sensitive patients with asthma and rhinosinusitis, and tryptase and histamine levels were measured in their venous blood samples."3.68Tryptase and histamine release during aspirin-induced respiratory reactions. ( Bosso, JV; Schwartz, LB; Stevenson, DD, 1991)
"Inhalation and nasal aspirin challenge has been investigated in asthma patients with co-existing rhinitis."3.68Inhalation and nasal challenge in the diagnosis of aspirin-induced asthma. ( Davies, BH; Pawlowicz, A; Williams, WR, 1991)
"One hundred seven known aspirin (ASA)-sensitive patients with rhinosinusitis-asthma were studied from 1975 to 1988."3.68Long-term effects of aspirin desensitization--treatment for aspirin-sensitive rhinosinusitis-asthma. ( Mathison, DA; Simon, RA; Stevenson, DD; Sweet, JM, 1990)
"Aspirin-sensitive asthma is not well documented in children."3.66Aspirin-induced asthma in children. ( Collins-Williams, C; Tan, Y, 1982)
"Eleven patients with asthma and aspirin hypersensitivity have been challenged with eight non-steroidal anti-inflammatory drugs."3.65Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. ( Czerniawska-Mysik, G; Gryglewski, RJ; Szczeklik, A, 1975)
"The aspirin intolerance syndrome is characterized by rhinitis and/or sinusitis, nasal polyposis and asthma, with or without a history of adverse reactions, following aspirin ingestion."3.65Intolerance to aspirin. ( Casterline, CL, 1975)
"Rhinosinusitis is among the most common infectious complications of humoral immunodeficiency, which is not uncommon in patients with refractory CRS."2.46Rhinosinusitis and comorbidities. ( Brooks, EG; Ryan, MW, 2010)
"Chronic rhinosinusitis is often associated with bronchial asthma."2.45[Chronic rhinosinusitis in morbus widal: clinical aspects and therapeutic options]. ( Jung, H, 2009)
"Rhinosinusitis is among the most common infectious complications of humoral immunodeficiency, and humoral immunodeficiency is not uncommon in patients with refractory chronic rhinosinusitis."2.44Diseases associated with chronic rhinosinusitis: what is the significance? ( Ryan, MW, 2008)
"Eosinophilia is frequently, but not exclusively, caused by immunoglobulin (Ig)E-mediated hypersensitivity and is dominated by the associated cytokine milieu of Th2 inflammation."2.43Differential diagnosis of eosinophilic chronic rhinosinusitis. ( Ferguson, BJ; Sok, JC, 2006)
"Bronchial asthma is not a homogenous disease."2.41Diagnosis, prevention and treatment of aspirin-induced asthma and rhinitis. ( Bánska, K; Bochenek, G; Nizankowska, E; Szabó, Z; Szczeklik, A, 2002)
"Nasal polyps are histologically characterized by massive edema and accumulation of eosinophils."2.39Eosinophils in the pathophysiology of nasal polyposis. ( Jankowski, R, 1996)
"Treatment of the nasal polyps has been shown to improve the patients' asthma."2.38Nasal polyps, bronchial asthma and aspirin sensitivity. ( Hawke, M; Jeney, E; Probst, L; Stoney, P, 1992)
" Long-term administration of acetylsalicylic acid (ASA) after desensitization has been used to mitigate these sequelae, but the optimal dose and balancing symptom relief and side effects remain unsettled."1.56Symptom Control of Patients With Chronic Rhinosinusitis With Nasal Polyps Under Maintenance Therapy With Daily Acetylsalicylic Acid. ( Appel, H; Greve, J; Hahn, J; Hoffmann, TK; Lindemann, J; Petereit, F; Scheithauer, MO; Sommer, F; Veit, JA, 2020)
"Aspirin sensitivity has a highly significant association with AFRS."1.48Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study. ( Ahmed, S; Almeyda, R; Anari, S; Carrie, S; Cathcart, R; Clark, A; Coombes, E; Erskine, S; Farboud, A; Hobson, J; Hopkins, C; Jervis, P; Kara, N; Khalil, H; Kumar, N; Mansell, N; Panesaar, J; Philpott, C; Philpott, CM; Prinsley, P; Ray, J; Robertson, A; Salam, M; Sunkaraneni, S; Sunkaraneni, V; Wilson, A; Woods, J, 2018)
"Prednisone was the most common OCS prescribed."1.46Oral corticosteroid prescribing habits for rhinosinusitis: The American Rhinologic Society membership. ( Ernst, HM; Rotenberg, BW; Rudmik, L; Scott, JR; Sowerby, LJ, 2017)
"Sinusitis is both prevalent and costly, affecting more than 14% of the population and costing more than $3."1.30Medical management of sinusitis. ( Kaliner, M, 1998)
"Tissue eosinophilia is regulated by chemical attractants and activating substances of various origins and plays a major part in the chronic inflammatory state."1.28Nonallergic rhinitis with eosinophilia syndrome a precursor of the triad: nasal polyposis, intrinsic asthma, and intolerance to aspirin. ( Guyot, JL; Hsieh, V; Maria, Y; Moneret-Vautrin, DA; Mouton, C; Wayoff, M, 1990)

Research

Studies (205)

TimeframeStudies, this research(%)All Research%
pre-199034 (16.59)18.7374
1990's15 (7.32)18.2507
2000's60 (29.27)29.6817
2010's56 (27.32)24.3611
2020's40 (19.51)2.80

Authors

AuthorsStudies
Wangberg, H2
Spierling Bagsic, SR2
Osuna, L1
White, AA5
Bertlich, M1
Ihler, F1
Bertlich, I1
Weiss, BG1
Gröger, M2
Haubner, F1
Quint, T2
Dahm, V1
Ramazanova, D1
Arnoldner, MA1
Kurz, H1
Janik, S1
Brunner, PM1
Knerer-Schally, B1
Weninger, W1
Griss, J1
Ristl, R1
Schneider, S2
Bangert, C2
D'Souza, GE1
Nwagu, U1
Barton, B1
Unsal, AA1
Rabinowitz, MR1
Rosen, MR1
Nyquist, GG1
Cohn, J1
Most, J1
Toskala, EM1
Talat, R1
Gengler, I1
Phillips, KM1
Caradonna, DS1
Gray, ST1
Sedaghat, AR1
Tripathi, SH1
Kumar, A1
Kohanski, MA2
Kennedy, DW1
Palmer, JN1
Adappa, ND1
Bosso, JV3
Wallace, DV1
Laidlaw, TM7
Chu, DK2
Stevens, WW5
Miss Ozuna, L1
Ryan, T2
Bensko, JC3
Buchheit, KM8
Sohail, A1
Hacker, J2
Maurer, R3
Gakpo, D1
Taliaferro, F1
Ordovas-Montanes, J1
Aydin, Ö1
Atmiş, EÖ1
Anadolu, Y1
Yorulmaz, İ1
Çelik, GE1
Walters, BK1
Hagan, JB1
Divekar, RD1
Willson, TJ1
Stokken, JK1
Pinheiro-Neto, CD1
O'Brien, EK1
Choby, G1
Rank, MA1
Bognanni, A1
Oykhman, P1
Bernstein, JA2
Ellis, AK1
Golden, DBK1
Greenhawt, M1
Horner, CC1
Ledford, DK1
Lieberman, J1
Luong, AU1
Orlandi, RR1
Samant, SA1
Shaker, MS1
Soler, ZM1
Stukus, DR1
Wang, J1
Peters, AT1
Poglitsch, K1
Morgenstern, C1
Gangl, K1
Sinz, C1
Bartosik, T1
Campion, NJ1
Liu, DT1
Landegger, LD1
Tu, A1
Stanek, V1
Rocha-Hasler, M1
Eckl-Dorna, J1
Perić, A3
Gaćeša, D2
Cvetković, G1
Vojvodić, D1
Cahill, KN4
Alfallaj, R1
Obaid, SB1
Almousa, H1
Ismail, D1
Mahjoub, S1
Alanazy, F1
Dousary, SA1
Alromaih, S1
Aloulah, M1
Alrasheed, A1
Alroqi, AS1
Alsaleh, S1
Mullur, J1
McGill, A1
Supron, AD1
Bergmark, RW2
Roditi, RE1
Adame, MJ1
Raji, M1
Shan, Y1
Zhang, Y1
Kuo, YF1
Tripple, JW1
Vukadinović, T1
Vuksanović Božarić, A1
Vukomanović Đurđević, B1
Radunović, M1
San Nicoló, M1
Högerle, C1
Gellrich, D1
Eder, K1
Pfrogner, E1
Larivée, N1
Chin, CJ1
Hahn, J1
Appel, H1
Scheithauer, MO1
Petereit, F1
Greve, J1
Lindemann, J1
Hoffmann, TK1
Veit, JA1
Sommer, F1
Alanin, MC1
Laidlaw, T2
Society, TS1
Hopkins, C4
McHugh, T1
Levin, M1
Snidvongs, K1
Banglawala, SM1
Sommer, DD2
Grose, E1
Lee, DJ1
Yip, J1
Cottrell, J1
Sykes, J1
Lee, JK1
Lee, JM1
Malfitano, MJ1
Santarelli, GD1
Gelpi, M1
Brown, WC1
Stepp, WH1
Hernandez, S1
Kimple, AJ1
Thorp, BD1
Zanation, AM1
Ebert, CS1
Jakiela, B1
Soja, J1
Sladek, K1
Przybyszowski, M1
Plutecka, H2
Gielicz, A3
Rebane, A1
Bochenek, G3
Mustafa, SS1
Vadamalai, K1
Scott, B1
Ramsey, A1
Jerschow, E2
Baptist, AP1
Borish, L2
Campo, P1
Cho, SH1
Keswani, A1
Levy, JM3
Nanda, A1
Palumbo, M1
Rahman, S1
Dominas, C1
Roditi, R1
Bhattacharyya, N1
Maxfield, A1
Espersen, J1
Weber, U1
Römer-Franz, A1
Lenarz, T1
Stolle, SRO1
Warnecke, A1
Cook, KA2
Domissy, A1
Simon, RA11
Modena, BD1
White, A1
Arshi, S2
Darougar, S1
Nabavi, M2
Bemanian, MH2
Fallahpour, M2
Shokri, S1
Ahmadian, J1
Molatefi, R1
Rekabi, M1
Moinfar, Z1
Hashemitari, P1
Eslami, N1
Sehanobish, E1
Asad, M1
Barbi, M1
Porcelli, SA1
Yong, M1
Wu, YQ1
Howlett, J1
Ballreich, J1
Walgama, E1
Thamboo, A1
Cohen, NA1
Barrett, NA1
Rodríguez-Jiménez, JC1
Moreno-Paz, FJ1
Terán, LM1
Guaní-Guerra, E1
Walters, KM1
Waldram, JD3
Woessner, KM3
Philpott, CM1
Erskine, S2
Kumar, N2
Anari, S2
Kara, N2
Sunkaraneni, S1
Ray, J2
Clark, A2
Wilson, A1
Philpott, C1
Robertson, A1
Ahmed, S1
Carrie, S1
Sunkaraneni, V1
Jervis, P1
Panesaar, J1
Farboud, A1
Cathcart, R1
Almeyda, R1
Khalil, H1
Prinsley, P1
Mansell, N1
Salam, M1
Hobson, J1
Woods, J1
Coombes, E1
Yamaguchi, T1
Ishii, T2
Yamamoto, K1
Higashi, N3
Taniguchi, M3
Okamoto, M1
Weinstein, SF1
Katial, RK3
Bardin, P1
Korn, S1
McDonald, M1
Garin, M1
Bateman, ED1
Hoyte, FCL1
Germinaro, M1
Eid, RC1
Palumbo, ML1
DeGregorio, GA1
Singer, J1
Doña, I1
Barrionuevo, E1
Salas, M1
Laguna, JJ1
Agúndez, J1
García-Martín, E1
Bogas, G1
Perkins, JR1
Cornejo-García, JA1
Torres, MJ1
Kowalski, ML8
Cooper, T1
Greig, SR1
Zhang, H1
Seemann, R1
Wright, ED1
Vliagoftis, H1
Côté, DWJ1
Kovačević, SV1
Barać, A1
Perić, AV1
Jožin, SM1
Förster-Ruhrmann, U1
Behrbohm, W1
Pierchalla, G1
Szczepek, AJ1
Fluhr, JW1
Olze, H1
Cleland, EJ1
Bassiouni, A1
Wormald, PJ2
Mullol, J4
Picado, C5
Karakaya, G1
Celebioglu, E1
Kalyoncu, AF1
Jang, DW1
Comer, BT1
Lachanas, VA1
Kountakis, SE3
Miller, B1
Mirakian, R2
Gane, S1
Larco, J1
Sannah, AA1
Darby, Y1
Scadding, G3
Kutlu, A1
Salihoglu, M1
Haholu, A1
Cesmeci, E1
Cincik, H1
Ozturk, S1
Edward, JA1
Sanyal, M1
Ramakrishnan, VR2
Le, W1
Nguyen, AL1
Kingdom, TT3
Hwang, PH2
Nayak, JV2
Klimek, L1
Dollner, R1
Pfaar, O1
Parikh, A3
Scadding, GK2
Świerczyńska-Krępa, M2
Sanak, M5
Stręk, P2
Ćmiel, A1
Szczeklik, A7
Niżankowska-Mogilnicka, E4
Montone, KT1
Cho, KS1
Soudry, E1
Psaltis, AJ1
Nadeau, KC1
McGhee, SA1
Machado-Carvalho, L1
Roca-Ferrer, J2
Hoffbauer, S1
Au, M1
Sowerby, LJ2
Gupta, MK1
Nayan, S1
Dazy, KM2
Matsusaka, M1
Kabata, H1
Fukunaga, K1
Suzuki, Y1
Masaki, K1
Mochimaru, T1
Sakamaki, F1
Oyamada, Y1
Inoue, T1
Oguma, T1
Sayama, K1
Koh, H1
Nakamura, M1
Umeda, A1
Ono, J1
Ohta, S1
Izuhara, K1
Asano, K1
Betsuyaku, T1
DeConde, AS1
Suh, JD1
Mace, JC1
Alt, JA1
Smith, TL3
Esmaeilzadeh, H1
Aryan, Z1
Mortazavi, N1
Makowska, J1
Lewandowska-Polak, A1
Wojtczak, A1
Skrętkowicz, J1
Szabó, K1
Polyánka, H1
Kiricsi, Á1
Révész, M1
Vóna, I1
Szabó, Z2
Bella, Z1
Kadocsa, E1
Kemény, L1
Széll, M1
Hirschberg, A1
Pezato, R1
Holtappels, G2
De Ruyck, N1
Derycke, L1
Van Crombruggen, K1
Bachert, C5
Pérez-Novo, CA1
Zhang, L1
Gevaert, P3
Gitomer, SA1
Fountain, CR1
Getz, AE1
Sillau, SH1
Adelman, J1
McLean, C1
Shaigany, K1
Krouse, JH1
Dunn, NM1
Fruth, K2
Gosepath, J4
Sakalar, EG1
Muluk, NB1
Kar, M1
Cingi, C1
Schleimer, RP1
Stevenson, DD10
Gudziol, V2
Michel, M1
Sonnefeld, C1
Koschel, D1
Hummel, T2
Scott, JR1
Ernst, HM1
Rotenberg, BW1
Rudmik, L1
Williams, AN1
Yoshimura, T1
Yoshikawa, M1
Otori, N1
Haruna, S1
Moriyama, H1
Caversaccio, M1
Häusler, R1
Helbling, A1
Das, S1
Maeso, PA1
Becker, AM1
Prosser, JD1
Adam, BL1
Platt, M1
Metson, R1
Stankovic, K1
Jung, H1
Di Leo, E1
Nettis, E1
Calogiuri, GF1
Ferrannini, A1
Vacca, A1
Cardona, R1
Ramírez, RH1
Reina, Z1
Escobar, MF1
Morales, E1
Schachtel, BP1
Voelker, M1
Sanner, KM1
Gagney, D1
Bey, M1
Schachtel, EJ1
Becka, M1
Ryan, MW2
Brooks, EG1
Wood, AJ1
Douglas, RG1
Rizk, H1
Riabova, MA1
Shumilova, NA1
Merkonidis, C1
Cecchini, MP1
Gerber, J1
Seo, HS1
Goebel, G1
Koutsimpelas, D1
Schmidtmann, I1
Mann, WJ3
Brieger, J1
Celejewska-Wójcik, N1
Mastalerz, L2
Wójcik, K1
Nieckarz, R1
Januszek, R1
Hartwich, P1
Szaleniec, J1
Hydzik-Sobocińska, K1
Oleś, K1
Cybulska, A1
Shikani, AH1
Kourelis, K1
Rohayem, Z1
Basaraba, RJ1
Leid, JG1
Mita, H2
Osame, M2
Akiyama, K2
Berges-Gimeno, MP3
Namazy, JA1
Paganin, F1
Poubeau, P1
Yvin, JL1
Arvin-Berod, C1
DUGAS, M1
MILLER, J1
ABRUZZI, WA1
DE VARENNE, D1
Fox, RW1
Lockey, RF2
Bánska, K1
Nizankowska, E3
Swierczynska, M2
Zarychta, J1
Groneberg, DA1
Heppt, W1
Welker, P1
Peiser, C1
Dinh, QT1
Cryer, A1
Zweng, M1
Witt, C1
Fischer, A1
Kiełbasa, B1
Kawagishi, Y1
Higashi, A1
Pujols, L1
Alobid, I1
Xaubet, A1
Van Zele, T2
Watelet, JB1
Claeys, G1
Claeys, C1
van Cauwenberge, P2
Gollapudi, RR1
Teirstein, PS1
Corrigan, C1
Mallett, K1
Ying, S2
Roberts, D1
Lee, T1
Celik, G2
Paşaoğlu, G1
Bavbek, S2
Abadoğlu, O1
Dursun, B1
Mungan, D2
Misirligil, Z2
Cormican, LJ1
Farooque, S1
Altmann, DR1
Lee, TH3
Ptasinska, A1
Jedrzejczak, M1
Bienkiewicz, B2
Cieslak, M1
Grzegorczyk, J2
Pawliczak, R2
Dubuske, L1
de Weck, A1
Sanz, ML1
Gamboa, P1
Meng, Q1
Corrigan, CJ1
Micheletto, C1
Visconti, M1
Tognella, S1
Facchini, FM1
Dal Negro, RW1
Lee, JY1
Sok, JC2
Ferguson, BJ2
Owens, JM1
Shroyer, KR1
Modrzyński, M1
Mazurek, H1
Zawisza, E1
Kim, SH1
Park, HS1
Holloway, JW1
Shin, HD1
Park, CS1
Specjalski, K1
Chełmińska, M1
Smith, WB1
Magnan, A1
Macy, E1
Castells, MC1
Gawchik, SM1
Settipane, RA1
Wald, J1
Robinson, JL1
Griest, S1
James, KE1
Zhang, N1
Patou, J1
Slavin, RG1
Kim, JE1
Browne, JP1
Slack, R1
Lund, V1
Brown, P1
Durham, SR1
Jones, NS1
Drake-Lee, AB1
Ryan, D1
Dixon, TA1
Huber, PA1
Nasser, SM1
Salib, RJ1
Harries, PG1
Nair, SB1
Howarth, PH1
Joe, SA1
Thakkar, K1
Settipane, GA3
Pleskow, WW1
Mathison, DA3
Lumry, WR2
Schatz, M1
Zeiger, RS1
Curd, JG1
Scherrer, M1
Zeller, C1
Berger, M1
Enzmann, H1
Rieben, FW1
Tan, Y1
Collins-Williams, C1
Rosenhall, L1
Saldi, M1
Swierczyński, Z1
Samoliński, B1
Krzeski, A1
Sliwinska-Kowalska, M1
Igarashi, Y1
White, MV1
Wojciechowska, B1
Brayton, P1
Kaulbach, H1
Rozniecki, J1
Kaliner, MA1
Jankowski, R2
Senna, GE1
Passalacqua, G1
Andri, G1
Dama, AR1
Albano, M1
Fregonese, L1
Andri, L1
Sánchez-Borges, M1
Capriles-Hulett, A1
Capriles-Behrens, E1
Fernandez-Caldas, E1
Milewski, M1
Duplaga, M1
Kaliner, M1
Atamuradov, MA1
Garaev, TA1
Sturtevant, J1
Ediger, D1
Demirel, YS1
Kordek, P1
Studniarek, M1
Kośny, B1
Casadevall, J1
Ventura, PJ1
May, A1
Wagner, D1
Langenbeck, U1
Weber, A1
Babu, KS1
Salvi, SS1
Schaefer, D1
Amedee, RG1
Mardiney, M1
Kornatowski, T1
Wagrowska-Danilewicz, M1
Danilewicz, M1
Mygind, N1
Gorenberg, D1
Lewis, DP1
Casterline, CL2
Stein, M1
Vedanthan, PK1
Menon, MM1
Bell, TD1
Bergin, D1
Faidi, AR1
Gryglewski, RJ1
Czerniawska-Mysik, G1
Stenius, BS1
Lemola, M1
Probst, L1
Stoney, P1
Jeney, E1
Hawke, M1
Schwartz, LB1
Pawlowicz, A1
Williams, WR1
Davies, BH1
Sweet, JM1
Moneret-Vautrin, DA2
Hsieh, V2
Wayoff, M2
Guyot, JL1
Mouton, C1
Maria, Y2
Knight, A1
Ogino, S1
Harada, T1
Matsunaga, T1
Okawachi, I1
Irifune, M1
Nagano, T1
Gorichkina, LA1
Frolova, MK1
Kuria, VF1
Blue, JA1
Rucknagel, DL1
Vanselow, NA1
Marcoux, J1
Labbé, J1
Michaëlsson, G1
Juhlin, L1
Fisherman, EW2
Cohen, GN2
Samter, M1
Beers, RF1
Hawkins, D1
Pinckard, RN1
Farr, RS1

Clinical Trials (16)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Moving Towards PREcision Medicine In United Airways Disease: Unraveling inflaMmatory Patterns in Asthmatic Patients With or Without Nasal Polyps (PREMIUM) - a Descriptive Pilot Study[NCT05009758]30 participants (Anticipated)Interventional2021-09-01Recruiting
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma[NCT01287039]Phase 3489 participants (Actual)Interventional2011-04-30Completed
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma[NCT01285323]Phase 3464 participants (Actual)Interventional2011-03-31Completed
Dupilumab as add-on Therapy for Aspirin-exacerbated Respiratory Disease (AERD)[NCT03595488]Phase 211 participants (Actual)Interventional2018-09-05Completed
Improving Patient Care Via Proteomics Based, Microbe-Specific Detection of Chronic Rhinosinusitis[NCT00962689]38 participants (Actual)Observational2009-08-31Completed
Gel-Sinuplasty for Chronic Rhinosinusitis With and Without Nasal Polyposis[NCT03472144]Phase 360 participants (Anticipated)Interventional2017-07-07Recruiting
The Effect of Aspirin Desensitization on Patients With Aspirin-exacerbated Respiratory Diseases[NCT01867281]Phase 432 participants (Actual)Interventional2013-06-30Completed
Role of Doxycycline in the Management of Patients With Chronic Rhinosinusitis With Nasal Polyps[NCT05157412]Phase 360 participants (Anticipated)Interventional2022-03-01Not yet recruiting
Challenge Test for Acetylsalicylic Acid Hypersensitivity[NCT01681615]50 participants (Anticipated)Interventional2012-09-30Not yet recruiting
Determinants of Surgical Outcomes in Chronic Sinusitis[NCT00799097]516 participants (Actual)Observational2004-07-31Completed
Effect of Thymoquinone and Olive Oil on Wound Healing After Endoscopic Sinus Surgery in Patients With Nasal Polyposis[NCT06070311]50 participants (Anticipated)Interventional2023-10-31Not yet recruiting
Role of Short Term Systemic Corticosteroid Therapy in the Management of Chronic Rhinosinusitis Without Nasal Polyps[NCT01676415]Phase 49 participants (Actual)Interventional2012-08-31Terminated (stopped due to participants are no longer receiving intervention due to clinical logistics)
High Volume Saline Irrigation in the Post-operative Management of Chronic Rhinosinusitis: A Multicenter Randomized Single-Blind Controlled Trial[NCT02636959]Early Phase 120 participants (Anticipated)Interventional2015-12-31Recruiting
Role of Epithelial Barrier Integrity in Biologic Treatment Response of Severe Asthmatics With/Out Chronic Rhinosinusitis With Nasal Polyps (CRSwNP). Can Shedding of Epithelial Barrier Proteins be Used as Biomarker in Severe Asthma With/Out CRSwNP Manageme[NCT05365841]85 participants (Anticipated)Observational2022-05-15Not yet recruiting
Ideal Frequency of Postoperative High Volume Saline Irrigations Following Endoscopic Sinus Surgery[NCT01680705]75 participants (Actual)Interventional2012-07-31Completed
Role of Montelukast in the Management of Chronic Rhinosinusitis With Nasal Polyps.[NCT05143502]Phase 1/Phase 260 participants (Anticipated)Interventional2022-01-01Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Asthma Control Questionnaire (ACQ) Over 16 Weeks Using Mixed Model for Repeated Measures

"The ACQ is a 7-item instrument that measures asthma control (Juniper et al 1999). Six questions are self-assessments; the seventh item, completed by a member of the study staff, is the result of the patient's FEV1 measurement. Each item has 7 possible answers on a scale of 0 to 6, and the total score is the mean of all responses (the total scale is therefore 0-6). A higher score is an indication of poorer asthma control. The during treatment (Weeks 4, 8, 12 and 16) average ACQ was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Negative change from baseline scores indicate improvement in asthma control." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16

Interventionunits on a scale (Least Squares Mean)
Placebo-0.676
Reslizumab 3.0 mg/kg-0.941

Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) to Week 16

"The AQLQ is a 32-item instrument administered as a self-assessment (Juniper et al 1992). The questionnaire is divided into 4 domains: activity limitation, symptoms, emotional function, and environmental stimuli. Patients were asked to recall their experiences during the last 2 weeks and to respond to each question on a 7-point scale (1=severe impairment, 7=no impairment). The overall AQLQ score is the mean of all 32 responses. Five of the activity questions were patient-specific, which means that each patient identified and scored 5 activities in which the patient was limited by asthma; these 5 activities were identified at the first visit and retained for all subsequent follow-up visits.~Positive change from baseline scores indicate improvement in quality of life." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Week 16

Interventionunits on a scale (Least Squares Mean)
Placebo0.695
Reslizumab 3.0 mg/kg0.933

Change From Baseline in Asthma Symptom Utility Index (ASUI) Over 16 Weeks Using Mixed Model for Repeated Measures

"The ASUI is an 11-item instrument designed to assess the frequency and severity of asthma symptoms and side effects, weighted by patient preferences (Revicki et al 1998). ASUI is a utility score that ranges from 0 to 1, with higher values indicating better asthma control; info obtained from questionnaire about asthma symptoms.~The during treatment (Weeks 4, 8, 12 and 16) average ASUI was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Positive change from baseline values indicate improvement in asthma symptoms. Information was obtained from questionnaire about asthma symptoms." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16

Interventionunits on a scale (Least Squares Mean)
Placebo0.109
Reslizumab 3.0 mg/kg0.167

Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Over 16 Weeks Using Mixed Model for Repeated Measures

"FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained from pulmonary function tests. It is the volume of air expired in the first second of a forced expiration using a spirometer. Positive change from baseline scores indicate improvement in asthma control.~The during treatment (Weeks 4, 8, 12 and 16) average FEV1 was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16

Interventionliters (Least Squares Mean)
Placebo0.110
Reslizumab 3.0 mg/kg0.248

Change From Baseline in Short-Acting Beta-Agonist (SABA) Use Over 16 Weeks Using Mixed Model for Repeated Measures

"SABA are used for quick relief of asthma symptoms. To measure SABA use, at each clinical visit patients were asked to recall their usage of SABA therapy within the last 3 days of the scheduled visit. If usage was confirmed, the number of puffs used was recorded. For the purpose of summaries, an average daily usage was evaluated by dividing the total number of puffs recorded over 3 days by 3.~The during treatment (Weeks 4, 8, 12 and 16) SABA use was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Negative change from baseline scores indicate improvement in asthma control." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16

Interventionpuffs/day (Least Squares Mean)
Placebo-0.36
Reslizumab 3.0 mg/kg-0.64

Frequency of Clinical Asthma Exacerbations (CAEs) During 12 Months of Treatment

"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization CAEs were adjudicated by committee to assure consistency.~Adjusted CAE rate and confidence intervals were based on Negative Binomial regression model adjusted for stratification factors.~Results are offered as adjusted means." (NCT01287039)
Timeframe: Day 1 to Week 52

InterventionCAEs in 52 weeks (Mean)
Placebo1.804
Reslizumab 3.0 mg/kg0.904

Kaplan-Meier Estimates for Time to First Clinical Asthma Exacerbation (CAE)

"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization.~CAEs were adjudicated by committee to assure consistency. The distributions were compared by a log rank test stratified by baseline usage of oral corticosteroid (yes or no) and geographical region (US or other)." (NCT01287039)
Timeframe: Day 1 to Day 478 (longest treatment time plus 2 weeks)

Interventionweeks (Median)
Placebo34.9
Reslizumab 3.0 mg/kgNA

Participants With a Positive Anti-Reslizumab Antibody Status During Study

The immunogenicity of reslizumab was assessed by measuring for the presence of anti-reslizumab antibodies at baseline, weeks 16, 32, 48, and 52 or early withdrawal. Blood samples for anti-reslizumab antibodies assessment were also obtained from all patients (inside or outside of the US) experiencing a serious adverse event, an adverse event leading to withdrawal, or an exacerbation of asthma symptoms. (NCT01287039)
Timeframe: Weeks 16, 32, 48 and 52

Interventionparticipants (Number)
Reslizumab 3.0 mg/kg8

Change From Baseline in Blood Eosinophil Count Over 16 Weeks and 52 Weeks Using Mixed Model for Repeated Measures

"Blood eosinophil counts were measured using a standard complete blood count (CBC) with differential blood test at each scheduled visit, and from all patients experiencing a serious adverse event, an adverse event leading to withdrawal, or an exacerbation of asthma symptoms.~The during treatment average eosinophil counts were estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Negative change from baseline values correlate to reduced asthma severity." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 or early withdrawal

,
Intervention10^9 blood eosinophil/L (Least Squares Mean)
Over first 16 weeksOver 52 weeks
Placebo-0.118-0.127
Reslizumab 3.0 mg/kg-0.584-0.582

Frequency of Each of the Two Criteria for Clinical Asthma Exacerbations (CAEs)

"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization.~CAEs were adjudicated by committee to assure consistency. Adjusted CAE rate and confidence intervals for the two criteria were based on Negative Binomial regression model adjusted for stratification factors.~Results are offered as adjusted means." (NCT01287039)
Timeframe: Day 1 to Week 52

,
InterventionCAEs in 52 weeks (Mean)
Requiring systemic corticosterioids >3 daysRequiring hospitalization or ER visit
Placebo1.6040.207
Reslizumab 3.0 mg/kg0.7220.137

Participants With Treatment-Emergent Adverse Events

An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an inability to carry out usual activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes. (NCT01287039)
Timeframe: Day 1 (post-dose) to Week 65. The last postbaseline value for approximately 20 patients in each

,
Interventionparticipants (Number)
At least 1 AEMild severity AEModerate severity AESevere AETreatment-related AETreatment-related mild AETreatment-related moderate AETreatment-related severe AEAE causing patient discontinuationSerious AEDeaths
Placebo206411333236231308341
Reslizumab 3.0 mg/kg19768107223624934240

Participants With Treatment-Emergent Potentially Clinically Significant (PCS) Abnormal Lab Values

"Data represents participants with potentially clinically significant (PCS) abnormal serum chemistry, hematology, and urinalysis values.~Significance criteria:~Blood urea nitrogen: >=10.71 mmol/L~Uric acid: M>=625, F>=506 μmol/L~Aspartate aminotransferase: >=3*upper limit of normal (ULN). Normal range is 10-43 U/L~Alanine aminotransferase: >=3*ULN. Normal range is 10-40 U/L~GGT = gamma-glutamyl transpeptidase: >= 3*ULN. Normal range is 5-49 U/L.~Bilirubin: >=34.2 μmol/L~White blood cells: <=3.0 or >20 10^9/L~Hemoglobin: M<=115, F<=95 g/dL~Hematocrit: M<0.37, F<0.32 L/L~Neutrophils: <=1.0 10^9/L~Eosinophils: >10.0 %~Platelets: <75 or >=700 10^9/L~Urinalysis: blood, glucose, ketones and total protein: >=2 unit increase from baseline" (NCT01287039)
Timeframe: Week 4 to Week 65. The last postbaseline value for approximately 20 patients in each

,
Interventionparticipants (Number)
Blood urea nitrogenUric acidAspartate aminotransferaseAlanine aminotransferaseGamma-glutamyl transpeptidaseBilirubinWhite blood cells - lowWhite blood cells - highHemoglobinHematocritNeutrophilsEosinophilsPlatelets - lowPlatelets - highUrinalysis - Blood (hemoglobin)Urinalysis - KetonesUrinalysis - GlucoseUrinalysis - Protein
Placebo991312265798135123241132
Reslizumab 3.0 mg/kg8615121634663202151434

Participants With Treatment-Emergent Potentially Clinically Significant (PCS) Vital Signs Values

"Data represents participants with potentially clinically significant (PCS) vital sign values.~Significance criteria~Sitting pulse - high 12-17 yr: >100 and increase of >= 30 beats/minute (bpm)~Sitting pulse - low >=18 yr: <50 and decrease of >=30 bpm~Sitting pulse - high >=18 yr: >100 and increase of >=30 bpm~Sitting systolic blood pressure - low >=18 yr: <90 and decrease of >=30 mmHg~Sitting systolic blood pressure - high >=18 yr: >160 and increase of >=30 mmHg~Sitting diastolic blood pressure - low 12-17 yr: <55 and decrease of >=12 mmHg~Sitting diastolic blood pressure - low >=18 yr: <50 and decrease of >=12 mmHg~Sitting diastolic blood pressure - high >=18 yr: >100 and increase of >=12 mmHg~Respiratory rate >=18 yr: >24 and increase of >=10 breaths/minute~Body temperature - low 12-17 yr: <96.5° Fahrenheit or <35.8° Celsius~Body temp - low >=18 yr: <96.5° F or <35.8° C~Body temp - high >=18 yr: >100.5° Fahrenheit" (NCT01287039)
Timeframe: Week 4 to Week 65. The last postbaseline value for approximately 20 patients in each

,
Interventionparticipants (Number)
Sitting pulse - high 12-17 yrSitting pulse - low >=18 yrSitting pulse - high >=18 yrSitting systolic blood pressure - low >=18 yrSitting systolic blood pressure - high >=18 yrSitting diastolic blood pressure - low 12-17 yrSitting diastolic blood pressure - low >=18 yrSitting diastolic blood pressure - high >=18 yrRespiratory rate >=18 yrBody temperature - low 12-17 yrBody temperature - low >=18 yrBody temperature - high >=18 yr
Placebo11527101031540
Reslizumab 3.0 mg/kg1075701521491

Change From Baseline in Asthma Control Questionnaire (ACQ) Over 16 Weeks Using Mixed Model for Repeated Measures

"The ACQ is a 7-item instrument that measures asthma control (Juniper et al 1999). Six questions are self-assessments; the seventh item, completed by a member of the study staff, is the result of the patient's FEV1 measurement. Each item has 7 possible answers on a scale of 0 to 6, and the total score is the mean of all responses (the total scale is therefore 0-6). A higher score is an indication of poorer asthma control. The during treatment (Weeks 4, 8, 12 and 16) average ACQ was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Negative change from baseline scores indicate improvement in asthma control." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16

Interventionunits on a scale (Least Squares Mean)
Placebo-0.660
Reslizumab 3.0 mg/kg-0.857

Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) to Week 16

"The AQLQ is a 32-item instrument administered as a self-assessment (Juniper et al 1992). The questionnaire is divided into 4 domains: activity limitation, symptoms, emotional function, and environmental stimuli. Patients were asked to recall their experiences during the last 2 weeks and to respond to each question on a 7-point scale (1=severe impairment, 7=no impairment). The overall AQLQ score is the mean of all 32 responses. Five of the activity questions were patient-specific, which means that each patient identified and scored 5 activities in which the patient was limited by asthma; these 5 activities were identified at the first visit and retained for all subsequent follow-up visits.~Positive change from baseline scores indicate improvement in quality of life." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Week 16

Interventionunits on a scale (Least Squares Mean)
Placebo0.777
Reslizumab 3.0 mg/kg0.987

Change From Baseline in Asthma Symptom Utility Index (ASUI) Over 16 Weeks Using Mixed Model for Repeated Measures

"The ASUI is an 11-item instrument designed to assess the frequency and severity of asthma symptoms and side effects, weighted by patient preferences (Revicki et al 1998). ASUI is a utility score that ranges from 0 to 1, with higher values indicating better asthma control; info obtained from questionnaire about asthma symptoms.~The during treatment (Weeks 4, 8, 12 and 16) average ASUI was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Positive change from baseline values indicate improvement in asthma symptoms. Information was obtained from questionnaire about asthma symptoms." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16

Interventionunits on a scale (Least Squares Mean)
Placebo0.080
Reslizumab 3.0 mg/kg0.115

Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) At Week 16

"FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained from pulmonary function tests. It is the volume of air expired in the first second of a forced expiration using a spirometer.~Positive change from baseline scores indicate improvement in asthma control." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Week 16

Interventionliters (Least Squares Mean)
Placebo0.122
Reslizumab 3.0 mg/kg0.223

Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Over 16 Weeks Using Mixed Model for Repeated Measures

"FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained from pulmonary function tests. It is the volume of air expired in the first second of a forced expiration using a spirometer. During study (Weeks 4, 8, 12 and 16) average value used a mixed effect model for repeated measures (MMRM) with treatment group, visit, treatment and visit interaction, and stratification factors as fixed effects and participant as a random effect. Covariates for baseline values were also included in the model; for pulmonary function test analyses, covariates for height and sex were included as well.~Positive change from baseline scores indicate improvement in asthma control." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16

Interventionliters (Least Squares Mean)
Placebo0.094
Reslizumab 3.0 mg/kg0.187

Change From Baseline in Short-Acting Beta-Agonist (SABA) Use Over 16 Weeks Using Mixed Model for Repeated Measures

"SABA are used for quick relief of asthma symptoms. To measure SABA use, at each clinical visit patients were asked to recall their usage of SABA therapy within the last 3 days of the scheduled visit. If usage was confirmed, the number of puffs used was recorded. For the purpose of summaries, an average daily usage was evaluated by dividing the total number of puffs recorded over 3 days by 3.~The during treatment (Weeks 4, 8, 12 and 16) average SABA use was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Negative change from baseline scores indicate improvement in asthma control." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16

InterventionSABA puffs per day (Least Squares Mean)
Placebo-0.44
Reslizumab 3.0 mg/kg-0.50

Frequency of Clinical Asthma Exacerbations (CAEs) During 12 Months of Treatment

"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization.~CAEs were adjudicated by committee to assure consistency. Adjusted CAE rate and confidence intervals were based on Negative Binomial regression model adjusted for stratification factors.~Results are offered as adjusted means." (NCT01285323)
Timeframe: Day 1 to Month 12

InterventionCAEs in 52 weeks (Mean)
Placebo2.115
Reslizumab 3.0 mg/kg0.859

Kaplan-Meier Estimates for Time to First Clinical Asthma Exacerbation (CAE)

"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization.~CAEs were adjudicated by committee to assure consistency. The distributions were compared by a log rank test stratified by baseline usage of oral corticosteroid (yes or no) and geographical region (US or other)." (NCT01285323)
Timeframe: Day 1 to Day 526 (longest treatment time plus 2 weeks)

Interventionweeks (Median)
PlaceboNA
Reslizumab 3.0 mg/kgNA

Change From Baseline in Blood Eosinophil Count Over 16 Weeks and 52 Weeks Using Mixed Model for Repeated Measures

"The blood eosinophil counts were measured using a standard complete blood count (CBC) with differential blood test. Results of all differential blood tests conducted after randomization were blinded.~The during treatment average eosinophil count was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements. The 'over 16 weeks' value used data from Weeks 4, 8, 12 and 16. The 'over 52 weeks' value used all the during study time points listed in the Time Frame field.~Negative change from baseline values correlate to reduced asthma severity." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 or early withdrawal

,
Intervention10^9 blood eosinophil/L (Least Squares Mean)
Over first 16 weeksOver 52 weeks
Placebo-0.076-0.076
Reslizumab 3.0 mg/kg-0.555-0.565

Frequency of Each of the Two Criteria for Clinical Asthma Exacerbations (CAEs)

"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization CAEs were adjudicated by committee to assure consistency.~Adjusted CAE rate and confidence intervals for the two criteria were based on Negative Binomial regression model adjusted for stratification factors.~Results are offered as adjusted means." (NCT01285323)
Timeframe: Day 1 to Month 12

,
InterventionCAEs in 52 weeks (Mean)
Requiring systemic corticosterioids >3 daysRequiring hospitalization or ER visit
Placebo1.6600.047
Reslizumab 3.0 mg/kg0.6460.033

Participants With a Positive Anti-Reslizumab Antibody Status During Study

Counts of participants with a positive anti-drug antibody (ADA) response during treatment is offered for the experimental treatment arm. Blood samples were collected for determination of ADAs before study drug infusion. (NCT01285323)
Timeframe: Baseline visit (prior to reslizumab exposure), Weeks 16, 32, 48 and 52

Interventionparticipants (Number)
BaselineWeek 16Week 32Week 48Week 52>=1 positive test result
Reslizumab 3.0 mg/kg101010101015

Participants With Treatment-Emergent Adverse Events TEAE)

An adverse event (AE) was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an inability to carry out usual activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes. (NCT01285323)
Timeframe: Day 1 (post-dose) to Week 65. The endpoint for adverse events was the last postbaseline observation, which included the 90 day follow-up visit.

,
Interventionparticipants (Number)
Any TEAEMild TEAEModerate TEAESevere TEAETreatment-related AEMild treatment-related AEModerate treatment-related AESevere treatment-related AETEAE causing patient discontinuationDeathsSerious AEs
Placebo201361402527141309023
Reslizumab 3.0 mg/kg17767981234221118018

Participants With Treatment-Emergent Potentially Clinically Significant (PCS) Abnormal Lab Values

"Data represents participants with potentially clinically significant (PCS) abnormal serum chemistry, hematology (except for eosinophil values), and urinalysis values.~Significance criteria:~Blood urea nitrogen: >=10.71 mmol/L~Creatinine: >=177 μmol/L~Urate: M>=625, F>=506 μmol/L~Aspartate aminotransferase (AST): >=3*upper limit of normal (ULN)~Alanine aminotransferase (ALT): >=3*ULN~GGT = gamma-glutamyl transpeptidase: >= 3*ULN~Total bilirubin: >=34.2 μmol/L~White blood cells (low): <=3.0*10^9/L~White blood cells (high): >=20*10^9/L~Hemoglobin (age >=18 years): M<=115, F<=95 g/dL~Hematocrit (age >=18 years): M<0.37, F<0.32 L/L~Eosinophils/leukocytes: >=10.0%~Platelets: <=75*10^9/L~Neutrophils: <=1.0*10^9/L~Urinalysis: blood, ketones, glucose, and protein: >=2 unit increase from baseline" (NCT01285323)
Timeframe: Week 4 to Week 52

,
Interventionparticipants (Number)
Blood urea nitrogenCreatinineUrateASTALTGGTBilirubinLeukocytes (low)Leukocytes (high)HemoglobinHematocritEosinophils/leukocytesPlateletsNeutrophilsUrine blood (hemoglobin)Urine ketonesUrine glucoseUrine protein
Placebo5053711330510168114286928
Reslizumab 3.0 mg/kg4122393101681019121728

Participants With Treatment-Emergent Potentially Clinically Significant (PCS) Vital Signs Values

"Data represents participants with potentially clinically significant (PCS) vital sign values.~Significance criteria~Sitting pulse (high): >100 and increase of >= 30 beats/minute~Sitting systolic blood pressure (low): <90 and decrease of >= 30 mmHg~Sitting systolic blood pressure (high): >160 and increase of >= 30 mmHg~Sitting diastolic blood pressure (low): <50 and decrease of >=12 mmHg (if 12-17 years old: <55 and decrease of >=12 mmHg 0~Sitting diastolic blood pressure (high): >100 and increase of >=12 mmHg~Respiratory rate (low): <6 breaths/minute~Respiratory rate (high): >24 and increase of >=10 breaths/minute~Body temperature (low): <35.8° Celsius~Body temperature (high): >=38.1 and increase of >=1.1° Celsius" (NCT01285323)
Timeframe: Week 4 to Week 52

,
Interventionparticipants (Number)
>=1 postbaseline vital sign abnormalitySitting pulse (high)Sitting systolic blood pressure (low)Sitting systolic blood pressure (high)Sitting diastolic blood pressure (low)Sitting diastolic blood pressure (high)Respiratory rate (low)Respiratory rate (high)Body temperature (low)Body temperature (high)
Placebo586204304501
Reslizumab 3.0 mg/kg496113415390

Medication Side-effect and Compliance Inventory

The medication side-effect and compliance inventory is a questionnaire to evaluate the frequency and severity of common side effects associated with the medications used in this study. (NCT01676415)
Timeframe: 4-6 weeks and 3 months after initiation of treatment

InterventionParticipants (Count of Participants)
Prednisone0
Topical Mometasone0

Taskforce Symptom Inventory

Change from baseline in individual symptom severity. The taskforce symptom inventory is a visual analog scale of the severity of the 4 major symptoms making up the clinical diagnostic criteria of CRS. (NCT01676415)
Timeframe: 4-6 weeks and 3 months after initiation of treatment

InterventionParticipants (Count of Participants)
Prednisone0
Topical Mometasone0

SNOT-22 Questionnaire

"The Sino-nasal Outcome Test-22 is a validated questionnaire that measures 22 nasal and quality of life symptoms (nasal obstruction and loss of smell and taste) ranked from 0 (not a problem) to 5 (problem as bad as it can be).~Min score= 0, Max score= 110 (worst possible problem on all symptoms)~Change from baseline of the SNOT-22 score. The SNOT-22 questionnaire is a 22-item disease-specific health related quality of life instrument validated for use in chronic rhinosinusitis." (NCT01676415)
Timeframe: 4-6 weeks and 3 months after initiation of treatment

,
Interventionunits on a scale (Mean)
4-6 WEEKS3 MONTHS
Prednisone45.7549
Topical Mometasone34.434.4

Reviews

63 reviews available for aspirin and Nasal Catarrh

ArticleYear
Treatment options for chronic rhinosinusitis with nasal polyps.
    Allergy and asthma proceedings, 2021, 11-01, Volume: 42, Issue:6

    Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Aspirin; Asthma; Biological Products; Chronic Diseas

2021
Controversies in Allergy: Aspirin Desensitization or Biologics for Aspirin-Exacerbated Respiratory Disease-How to Choose.
    The journal of allergy and clinical immunology. In practice, 2022, Volume: 10, Issue:6

    Topics: Aspirin; Asthma, Aspirin-Induced; Biological Products; Chronic Disease; Desensitization, Immunologic

2022
Aspirin-Exacerbated Respiratory Disease and the Unified Airway: A Contemporary Review.
    Otolaryngologic clinics of North America, 2023, Volume: 56, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma, Aspirin-Induced; Chronic Disease;

2023
Aspirin-exacerbated respiratory disease: Updates in the era of biologics.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2023, Volume: 131, Issue:3

    Topics: Aspirin; Asthma; Asthma, Aspirin-Induced; Biological Products; Chronic Disease; Humans; Nasal Polyps

2023
Aspirin desensitization therapy in aspirin-exacerbated respiratory disease: a systematic review.
    International forum of allergy & rhinology, 2020, Volume: 10, Issue:4

    Topics: Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunologic; Humans; Nasal Polyps; Rhinitis; Sinu

2020
Comorbidities associated with eosinophilic chronic rhinosinusitis: A systematic review and meta-analysis.
    Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery, 2020, Volume: 45, Issue:4

    Topics: Aspirin; Asthma; Chronic Disease; Comorbidity; Eosinophilia; Humans; Nasal Polyps; Rhinitis; Severit

2020
The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy,
    The Journal of allergy and clinical immunology, 2021, Volume: 147, Issue:3

    Topics: Administration, Oral; Algorithms; Allergens; Animals; Anti-Inflammatory Agents; Aspirin; Asthma, Asp

2021
Aspirin Actions in Treatment of NSAID-Exacerbated Respiratory Disease.
    Frontiers in immunology, 2021, Volume: 12

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitization,

2021
Aspirin exacerbated respiratory disease: Current topics and trends.
    Respiratory medicine, 2018, Volume: 135

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Arachidonic Acid; Aspirin; A

2018
Heterogeneity of NSAID-Exacerbated Respiratory Disease: has the time come for subphenotyping?
    Current opinion in pulmonary medicine, 2019, Volume: 25, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Biomarkers; Chronic Disea

2019
Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease.
    Immunology and allergy clinics of North America, 2013, Volume: 33, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Hypersensitivity; Humans; Nasal Polyps; Respi

2013
Topical nasal lysine aspirin in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis with nasal polyposis.
    Expert review of clinical immunology, 2014, Volume: 10, Issue:5

    Topics: Administration, Intranasal; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Human

2014
The molecular genetics of inflammatory, autoimmune, and infectious diseases of the sinonasal tract: a review.
    Archives of pathology & laboratory medicine, 2014, Volume: 138, Issue:6

    Topics: Aspirin; Autoimmune Diseases; Churg-Strauss Syndrome; Granulomatosis with Polyangiitis; Humans; Infe

2014
Prostaglandin E2 receptors in asthma and in chronic rhinosinusitis/nasal polyps with and without aspirin hypersensitivity.
    Respiratory research, 2014, Aug-26, Volume: 15

    Topics: Animals; Aspirin; Asthma; Drug Hypersensitivity; Humans; Nasal Polyps; Receptors, Prostaglandin E, E

2014
Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD).
    Current allergy and asthma reports, 2015, Volume: 15, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Desensitization, Immunologic; Hum

2015
Aspirin-exacerbated respiratory disease: characteristics and management strategies.
    Expert review of clinical immunology, 2015, Volume: 11, Issue:7

    Topics: Animals; Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunologic; Humans; Nasal Polyps; Rhini

2015
Hypersensitivity to Aspirin and other NSAIDs: Diagnostic Approach in Patients with Chronic Rhinosinusitis.
    Current allergy and asthma reports, 2015, Volume: 15, Issue:8

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Drug Hypersensitivity; Humans; Rh

2015
[Hypersensitivity to acetylsalicylic acid].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 2015, Volume: 68, Issue:2

    Topics: Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity; Humans; Incidence; Nasal Polyps; Rhinitis;

2015
Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis.
    The Journal of allergy and clinical immunology, 2015, Volume: 136, Issue:6

    Topics: Adult; Antibodies, Monoclonal, Humanized; Aspirin; Asthma; Comorbidity; DNA, Catalytic; Drug Hyperse

2015
The Role of Surgery in Management of Samter's Triad: A Systematic Review.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2016, Volume: 155, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Drug Hypersensitivity; Endoscopy; Humans;

2016
Chronic Rhinosinusitis and Aspirin-Exacerbated Respiratory Disease.
    Immunology and allergy clinics of North America, 2016, Volume: 36, Issue:3

    Topics: Allergens; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chronic Disease; Disease Progre

2016
Aspirin Exacerbated Respiratory Disease.
    Advances in oto-rhino-laryngology, 2016, Volume: 79

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Rhinitis

2016
Aspirin-exacerbated respiratory disease and current treatment modalities.
    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2017, Volume: 274, Issue:3

    Topics: Algorithms; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, H

2017
Aspirin-Exacerbated Respiratory Disease as an Endotype of Chronic Rhinosinusitis.
    Immunology and allergy clinics of North America, 2016, Volume: 36, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Humans; Respiratory Tract Disease

2016
Is aspirin desensitization indicated for the treatment recalcitrant chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease?
    The Laryngoscope, 2017, Volume: 127, Issue:4

    Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Desensitization, Immunologic; Humans; Nasal Polyp

2017
Current complications and treatment of aspirin-exacerbated respiratory disease.
    Expert review of respiratory medicine, 2016, Volume: 10, Issue:12

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Desensit

2016
The clinical effectiveness of aspirin desensitization in chronic rhinosinusitis.
    Current allergy and asthma reports, 2008, Volume: 8, Issue:3

    Topics: Administration, Oral; Aspirin; Chronic Disease; Desensitization, Immunologic; Humans; Lysine; Nasal

2008
Gene-expression signatures of nasal polyps associated with chronic rhinosinusitis and aspirin-sensitive asthma.
    Current opinion in allergy and clinical immunology, 2009, Volume: 9, Issue:1

    Topics: Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity; Gene Expression Profiling; Humans; Nasal Po

2009
[Chronic rhinosinusitis in morbus widal: clinical aspects and therapeutic options].
    Praxis, 2009, Nov-18, Volume: 98, Issue:23

    Topics: Adrenal Cortex Hormones; Aspirin; Asthma; Chronic Disease; Desensitization, Immunologic; Drug Hypers

2009
[Allergy and intolerance to nonsteroidal antinflammatory drugs: successful desensitization in three cases].
    Biomedica : revista del Instituto Nacional de Salud, 2009, Volume: 29, Issue:2

    Topics: Adult; Anaphylaxis; Angioedema; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspi

2009
Rhinosinusitis and comorbidities.
    Current allergy and asthma reports, 2010, Volume: 10, Issue:3

    Topics: Anti-Bacterial Agents; Aspirin; Cystic Fibrosis; Humans; Hypersensitivity; Immunity, Humoral; Immuno

2010
Pathogenesis and treatment of chronic rhinosinusitis.
    Postgraduate medical journal, 2010, Volume: 86, Issue:1016

    Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bi

2010
Role of aspirin desensitization in the management of chronic rhinosinusitis.
    Current opinion in otolaryngology & head and neck surgery, 2011, Volume: 19, Issue:3

    Topics: Aspirin; Chronic Disease; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Nasal Polyps;

2011
Aspirin intolerance and nasal polyposis.
    Current allergy and asthma reports, 2002, Volume: 2, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Hypersensitivity; Eicosanoids; Eosinophils; H

2002
Sensitivity to nonsteroidal anti-inflammatory drugs.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2002, Volume: 89, Issue:6

    Topics: Acetaminophen; Adult; Anaphylaxis; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bleedin

2002
The impact of rhinosinusitis on asthma.
    Current allergy and asthma reports, 2003, Volume: 3, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Common Cold; Humans; Rhinitis; Rhinitis, A

2003
Diagnosis, prevention and treatment of aspirin-induced asthma and rhinitis.
    Current drug targets. Inflammation and allergy, 2002, Volume: 1, Issue:1

    Topics: Aspirin; Asthma; Cyclooxygenase Inhibitors; Humans; Leukotrienes; Prostaglandin-Endoperoxide Synthas

2002
Aspirin intolerance and the cyclooxygenase-leukotriene pathways.
    Current opinion in pulmonary medicine, 2004, Volume: 10, Issue:1

    Topics: Aspirin; Asthma; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Desensiti

2004
Nonsteroidal anti-inflammatory drug-induced reactions and desensitization.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2004, Volume: 41, Issue:4

    Topics: Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Cross Reactions; Cyclooxygenas

2004
Aspirin sensitivity: implications for patients with coronary artery disease.
    JAMA, 2004, Dec-22, Volume: 292, Issue:24

    Topics: Algorithms; Anaphylaxis; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Coron

2004
Current concepts in therapy of chronic rhinosinusitis and nasal polyposis.
    ORL; journal for oto-rhino-laryngology and its related specialties, 2005, Volume: 67, Issue:3

    Topics: Anti-Bacterial Agents; Antifungal Agents; Aspirin; Chronic Disease; Endoscopy; Eosinophilia; Histami

2005
Differential diagnosis of eosinophilic chronic rhinosinusitis.
    Current allergy and asthma reports, 2006, Volume: 6, Issue:3

    Topics: Animals; Aspirin; Chronic Disease; Diagnosis, Differential; Eosinophilia; Fungi; Humans; Hypersensit

2006
[Diagnosis and treatment of aspirin-induced asthma].
    Polskie Archiwum Medycyny Wewnetrznej, 2006, Volume: 115, Issue:4

    Topics: Aspirin; Asthma; Bronchial Provocation Tests; Desensitization, Immunologic; Dose-Response Relationsh

2006
[Allergy to non steroidal anti-inflammatory drugs].
    Revue des maladies respiratoires, 2006, Volume: 23, Issue:4 Pt 2

    Topics: Anaphylaxis; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bronchial Provoca

2006
Differential diagnosis of eosinophilic chronic rhinosinusitis.
    Clinical allergy and immunology, 2007, Volume: 19

    Topics: Aspirin; Chronic Disease; Diagnosis, Differential; Eosinophilia; Eosinophils; Humans; Mycoses; Rhini

2007
Aspirin-sensitive rhinosinusitis and asthma.
    Clinical allergy and immunology, 2007, Volume: 19

    Topics: Arachidonic Acid; Aspirin; Asthma; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Infl

2007
Staphylococcus aureus enterotoxins as immune stimulants in chronic rhinosinusitis.
    Clinical allergy and immunology, 2007, Volume: 20

    Topics: Animals; Aspirin; Chronic Disease; Enterotoxins; Humans; Immunoglobulin E; Mice; Nasal Mucosa; Nasal

2007
Medical management of rhinosinusitis comorbidities-asthma, aspirin sensitivity, gastroesophageal reflux, immune deficiencies.
    Clinical allergy and immunology, 2007, Volume: 20

    Topics: Aspirin; Asthma; Drug Hypersensitivity; Eosinophils; Gastroesophageal Reflux; Humans; Immunologic De

2007
Mechanisms and mediators of nasal symptoms in non-allergic rhinitis.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2008, Volume: 38, Issue:3

    Topics: Administration, Topical; Air; Aspirin; Cold Temperature; Food; Hormones; Humans; Nasal Decongestants

2008
Chronic rhinosinusitis and asthma.
    Otolaryngologic clinics of North America, 2008, Volume: 41, Issue:2

    Topics: Aspirin; Asthma; Chronic Disease; Comorbidity; Drug Hypersensitivity; Humans; Lymphocytes; Nasal Muc

2008
Diseases associated with chronic rhinosinusitis: what is the significance?
    Current opinion in otolaryngology & head and neck surgery, 2008, Volume: 16, Issue:3

    Topics: Aspirin; Chronic Disease; Cystic Fibrosis; Humans; Hypersensitivity; Immunocompromised Host; Inciden

2008
Aspirin and allergic diseases: a review.
    The American journal of medicine, 1983, Jun-14, Volume: 74, Issue:6A

    Topics: Aspirin; Asthma; Bronchial Spasm; Cross Reactions; Desensitization, Immunologic; Drug Hypersensitivi

1983
[The classification of nonallergic eosinophilic rhinitis and sinus].
    Otolaryngologia polska = The Polish otolaryngology, 1994, Volume: 48 Suppl 17

    Topics: Age Factors; Aspirin; Asthma; Drug Tolerance; Eosinophils; Humans; Nasal Polyps; Neutrophils; Rhinit

1994
Eosinophils in the pathophysiology of nasal polyposis.
    Acta oto-laryngologica, 1996, Volume: 116, Issue:2

    Topics: Antigens, CD; Aspirin; Eosinophils; Fibroblasts; Granulocyte-Macrophage Colony-Stimulating Factor; H

1996
Nimesulide in the treatment of patients intolerant of aspirin and other NSAIDs.
    Drug safety, 1996, Volume: 14, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Humans; Rhinitis; Sulfonamides

1996
A new triad: sensitivity to aspirin, allergic rhinitis, and severe allergic reaction to ingested aeroallergens.
    Cutis, 1997, Volume: 59, Issue:6

    Topics: Adolescent; Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Hypersensitivity;

1997
Rhinosinusitis and nasal polyposis in aspirin sensitive and aspirin tolerant patients: are they different?
    Thorax, 2000, Volume: 55 Suppl 2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Humans; Nasal Polyps; R

2000
Aspirin and asthma.
    Chest, 2000, Volume: 118, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acids; Aspirin; Asthma; Bronchial Hyperreactivi

2000
Aspirin-induced rhinitis and asthma.
    Current opinion in allergy and clinical immunology, 2001, Volume: 1, Issue:1

    Topics: Aspirin; Asthma; Eicosanoids; Glutathione Transferase; Humans; Rhinitis; Sinusitis

2001
Immunohistopathology of allergic rhinitis and conditions allied.
    Clinical otolaryngology and allied sciences, 1978, Volume: 3, Issue:3

    Topics: Antigen-Antibody Reactions; Aspirin; Drug Tolerance; Eosinophils; Epithelium; Epitopes; Humans; Immu

1978
Tartrazine sensitivity and aspirin intolerance.
    Comprehensive therapy, 1977, Volume: 3, Issue:6

    Topics: Aspirin; Azo Compounds; Bronchial Spasm; Cross Reactions; Drug Hypersensitivity; Humans; Rhinitis; T

1977
Nasal polyps, bronchial asthma and aspirin sensitivity.
    The Journal of otolaryngology, 1992, Volume: 21, Issue:1

    Topics: Aspirin; Asthma; Drug Hypersensitivity; Humans; Nasal Polyps; Rhinitis; Syndrome

1992
Desensitization to aspirin in aspirin-sensitive patients with rhino-sinusitis and asthma: a review.
    The Journal of otolaryngology, 1989, Volume: 18, Issue:4

    Topics: Aspirin; Asthma; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Nasal Polyps; Rhinitis

1989

Trials

20 trials available for aspirin and Nasal Catarrh

ArticleYear
Dupilumab as Add-on Therapy for Chronic Rhinosinusitis With Nasal Polyposis in Aspirin Exacerbated Respiratory Disease.
    American journal of rhinology & allergy, 2021, Volume: 35, Issue:3

    Topics: Antibodies, Monoclonal, Humanized; Aspirin; Chronic Disease; Humans; Nasal Polyps; Quality of Life;

2021
The Effect of Aspirin on Moderate to Severe Asthmatic Patients with Aspirin Hypersensitivity, Chronic Rhinosinusitis, and Nasal Polyposis.
    Iranian journal of allergy, asthma, and immunology, 2021, Jun-06, Volume: 20, Issue:3

    Topics: Adult; Anti-Asthmatic Agents; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Double-Blind Method

2021
Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
    The journal of allergy and clinical immunology. In practice, 2019, Volume: 7, Issue:2

    Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies,

2019
Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
    The journal of allergy and clinical immunology. In practice, 2019, Volume: 7, Issue:2

    Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies,

2019
Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
    The journal of allergy and clinical immunology. In practice, 2019, Volume: 7, Issue:2

    Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies,

2019
Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
    The journal of allergy and clinical immunology. In practice, 2019, Volume: 7, Issue:2

    Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies,

2019
Efficacy of hypertonic (2.3%) sea water in patients with aspirin-induced chronic rhinosinusitis following endoscopic sinus surgery.
    Acta oto-laryngologica, 2019, Volume: 139, Issue:6

    Topics: Adult; Aspirin; China; Chronic Disease; Double-Blind Method; Endoscopy; Female; Humans; Male; Middle

2019
Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study.
    The Journal of allergy and clinical immunology, 2014, Volume: 134, Issue:4

    Topics: Administration, Oral; Adult; Aged; Allergens; Aspirin; Asthma; Asthma, Aspirin-Induced; Chronic Dise

2014
Treatment of aspirin exacerbated respiratory disease with a low salicylate diet: a pilot crossover study.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2015, Volume: 152, Issue:1

    Topics: Adult; Aged; Aspirin; Asthma; Cross-Over Studies; Desensitization, Immunologic; Drug Hypersensitivit

2015
Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: A randomized double-blind placebo-controlled trial.
    Clinical immunology (Orlando, Fla.), 2015, Volume: 160, Issue:2

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitization, I

2015
Systemic expression of inflammatory mediators in patients with chronic rhinosinusitis and nasal polyps with and without Aspirin Exacerbated Respiratory Disease.
    Cytokine, 2016, Volume: 77

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; C

2016
Demonstration of the analgesic efficacy and dose-response of acetylsalicylic acid with pseudoephedrine.
    Journal of clinical pharmacology, 2010, Volume: 50, Issue:12

    Topics: Adolescent; Adult; Analgesics, Non-Narcotic; Aspirin; Common Cold; Dose-Response Relationship, Drug;

2010
Topical gel therapy for sinonasal polyposis in Samter's triad: preliminary report.
    The Annals of otology, rhinology, and laryngology, 2012, Volume: 121, Issue:11

    Topics: Administration, Topical; Adult; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Aspirin; Asth

2012
[The effectiveness of leukotriene antagonists in the treatment of aspirin-intolerant asthmatic patients].
    Presse medicale (Paris, France : 1983), 2003, Jun-14, Volume: 32, Issue:21

    Topics: Acetates; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bleeding Time; Cyclopropa

2003
Nasal versus bronchial and nasal response to oral aspirin challenge: Clinical and biochemical differences between patients with aspirin-induced asthma/rhinitis.
    The Journal of allergy and clinical immunology, 2003, Volume: 112, Issue:5

    Topics: Administration, Oral; Adult; Aspirin; Asthma; Bronchi; Dinoprost; Female; Humans; Leukotriene E4; Ma

2003
Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2005, Volume: 42, Issue:2

    Topics: Adult; Anaphylaxis; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bronchial Spasm; Celecoxib; Cy

2005
[Nasal provocation test with lysine-aspirin in diagnosis of nonallergic rhinitis with eosinophilia].
    Otolaryngologia polska = The Polish otolaryngology, 2006, Volume: 60, Issue:1

    Topics: Administration, Intranasal; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; D

2006
Aspirin-sensitive rhinosinusitis asthma: a double-blind crossover study of treatment with aspirin.
    The Journal of allergy and clinical immunology, 1984, Volume: 73, Issue:4

    Topics: Aspirin; Asthma; Clinical Trials as Topic; Double-Blind Method; Drug Hypersensitivity; Forced Expira

1984
Intranasal fluticasone propionate for chronic eosinophilic rhinitis in patients with aspirin-induced asthma.
    Allergy, 1997, Volume: 52, Issue:9

    Topics: Administration, Intranasal; Adult; Androstadienes; Anti-Allergic Agents; Aspirin; Asthma; Chronic Di

1997
The use of nimesulide in patients with acetylsalicylic acid and nonsteroidal anti-inflammatory drug intolerance.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1999, Volume: 36, Issue:8

    Topics: Administration, Oral; Adult; Aged; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Ast

1999
[Point scale quantification of changes in computed tomography of chronic hyperplastic rhinosinusitis].
    Przeglad lekarski, 2000, Volume: 57, Issue:3

    Topics: Adult; Aspirin; Chronic Disease; Humans; Image Processing, Computer-Assisted; Middle Aged; Paranasal

2000
Aspirin and tartrazine oral challenge: incidence of adverse response in chronic childhood asthma.
    The Journal of allergy and clinical immunology, 1977, Volume: 60, Issue:1

    Topics: Adolescent; Aspirin; Asthma; Azo Compounds; Blood Pressure; Child; Chronic Disease; Clinical Trials

1977
Hypersensitivity to acetylsalicylic acid (ASA) and tartrazine in patients with asthma.
    Clinical allergy, 1976, Volume: 6, Issue:2

    Topics: Adolescent; Adult; Aged; Aging; Airway Obstruction; Aspirin; Asthma; Azo Compounds; Benzenesulfonate

1976

Other Studies

122 other studies available for aspirin and Nasal Catarrh

ArticleYear
Appraisal of the Real-World Effectiveness of Biologic Therapies in Aspirin-Exacerbated Respiratory Disease.
    The journal of allergy and clinical immunology. In practice, 2022, Volume: 10, Issue:2

    Topics: Aspirin; Asthma, Aspirin-Induced; Biological Therapy; Chronic Disease; Humans; Nasal Polyps; Pilot P

2022
Management of chronic rhinosinusitis with nasal polyps in Samter triad by low-dose ASA desensitization or dupilumab.
    Medicine, 2021, Oct-08, Volume: 100, Issue:40

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Aspirin; Chronic Dis

2021
Omalizumab-Induced Aspirin Tolerance in Nonsteroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease Patients Is Independent of Atopic Sensitization.
    The journal of allergy and clinical immunology. In practice, 2022, Volume: 10, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Humans; Nasal Polyps; Omalizumab;

2022
Outcomes of aspirin exacerbated respiratory disease patients treated with aspirin desensitization and biologics.
    International forum of allergy & rhinology, 2022, Volume: 12, Issue:3

    Topics: Aspirin; Asthma, Aspirin-Induced; Biological Products; Chronic Disease; Desensitization, Immunologic

2022
Chronic Rhinosinusitis Outcomes of Patients With Aspirin-Exacerbated Respiratory Disease Treated With Budesonide Irrigations: A Case Series.
    The Annals of otology, rhinology, and laryngology, 2022, Volume: 131, Issue:10

    Topics: Adrenal Cortex Hormones; Aspirin; Asthma, Aspirin-Induced; Budesonide; Chronic Disease; Humans; Nasa

2022
Comparison of aspirin desensitization outcomes between men and women with AERD.
    International forum of allergy & rhinology, 2022, Volume: 12, Issue:6

    Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Desensitization, Immunologic; Female; Humans; Mal

2022
Dupilumab-associated arthralgia in patients with aspirin-exacerbated respiratory disease.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2022, Volume: 128, Issue:4

    Topics: Antibodies, Monoclonal, Humanized; Arthralgia; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Hu

2022
Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease.
    The Journal of allergy and clinical immunology, 2022, Volume: 150, Issue:2

    Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Eicosanoids; Humans; Nasal Polyps; Prostaglandins

2022
Aspirin desensitization following endoscopic sinus surgery is effective in patients with nonsteroidal antiinflammatory drug exacerbated respiratory disease.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2023, Volume: 60, Issue:6

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma, Aspirin-Induced; Chronic Di

2023
The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis.
    The Journal of allergy and clinical immunology, 2023, Volume: 151, Issue:2

    Topics: Administration, Intranasal; Adrenal Cortex Hormones; Aspirin; Biological Products; Chronic Disease;

2023
Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease.
    The European respiratory journal, 2023, Volume: 61, Issue:3

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chronic Disease; Humans; Nasal Poly

2023
Inflammatory mediators in nasal secretions of patients with nasal polyposis with and without aspirin sensitivity.
    Immunity, inflammation and disease, 2023, Volume: 11, Issue:2

    Topics: Aspirin; Asthma, Aspirin-Induced; Cross-Sectional Studies; Humans; Inflammation Mediators; Nasal Pol

2023
Mechanistic and clinical updates in AERD: 2021-2022.
    The Journal of allergy and clinical immunology, 2023, Volume: 151, Issue:6

    Topics: Adult; Aspirin; Asthma; Asthma, Aspirin-Induced; Chronic Disease; Humans; Nasal Polyps; Rhinitis

2023
Demographic and clinical profile of patients with chronic rhinosinusitis in Saudi Arabia.
    Saudi medical journal, 2023, Volume: 44, Issue:4

    Topics: Aspirin; Asthma; Chronic Disease; Cross-Sectional Studies; Female; Humans; Male; Nasal Polyps; Preva

2023
Co-treatment of non-steroidal anti-inflammatory drug-exacerbated respiratory disease with dupilumab and aspirin therapy after desensitization.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2023, Volume: 53, Issue:9

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Aspirin; Asthma, Aspirin

2023
Perioperative mepolizumab in aspirin-exacerbated respiratory disease does not prevent nasal polyp regrowth.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2023, Volume: 131, Issue:3

    Topics: Antibodies, Monoclonal, Humanized; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Humans; Nasal

2023
Association Between Aspirin-Exacerbated Respiratory Disease and Atherosclerotic Cardiovascular Disease: A Retrospective Review of US Claims Data.
    The journal of allergy and clinical immunology. In practice, 2023, Volume: 11, Issue:11

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma, Aspirin-Induced; Cardiovascular Di

2023
Angiogenesis and eosinophilia in the nasal mucosa of patients with different clinical phenotypes of chronic rhinosinusitis.
    Journal of infection in developing countries, 2023, 10-31, Volume: 17, Issue:10

    Topics: Aspirin; Chronic Disease; Cross-Sectional Studies; Eosinophilia; Humans; Nasal Mucosa; Nasal Polyps;

2023
The time course of nasal cytokine secretion in patients with aspirin-exacerbated respiratory disease (AERD) undergoing aspirin desensitization: preliminary data.
    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2020, Volume: 277, Issue:2

    Topics: Adult; Aspirin; Asthma, Aspirin-Induced; Bodily Secretions; Chronic Disease; Cytokines; Desensitizat

2020
Symptom Control of Patients With Chronic Rhinosinusitis With Nasal Polyps Under Maintenance Therapy With Daily Acetylsalicylic Acid.
    American journal of rhinology & allergy, 2020, Volume: 34, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Desensit

2020
The Burden of Non-steroidal anti-inflammatory exacerbated respiratory disease from the patient's perspective - a qualitative analysis of posts from the Samter's Society.
    Rhinology, 2020, Aug-01, Volume: 58, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Cost of Illness; Drug Hypersensit

2020
Surgical outcomes in aspirin-exacerbated respiratory disease without aspirin desensitization.
    International forum of allergy & rhinology, 2020, Volume: 10, Issue:10

    Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Endoscopy; Humans; Nasal Polyps; Retrospective St

2020
A Comparison of Sphenoid Sinus Osteoneogenesis in Aspirin-Exacerbated Respiratory Disease.
    American journal of rhinology & allergy, 2021, Volume: 35, Issue:2

    Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Humans; Nasal Polyps; Retrospective Studies; Rhin

2021
Heterogeneity of lower airway inflammation in patients with NSAID-exacerbated respiratory disease.
    The Journal of allergy and clinical immunology, 2021, Volume: 147, Issue:4

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Biomarkers; Bronchoalveolar L

2021
Aspirin-Exacerbated Respiratory Disease: Association Between Patient-Reported Sinus and Asthma Morbidity.
    The journal of allergy and clinical immunology. In practice, 2021, Volume: 9, Issue:4

    Topics: Adult; Aspirin; Asthma; Chronic Disease; Female; Humans; Male; Middle Aged; Morbidity; Rhinitis

2021
Level of sex hormones and their association with acetylsalicylic acid intolerance and nasal polyposis.
    PloS one, 2020, Volume: 15, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Chronic Disease; Cone-Beam Computed Tomography; Drug Hypers

2020
Dysbiosis in aspirin-exacerbated respiratory disease.
    International forum of allergy & rhinology, 2021, Volume: 11, Issue:7

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Dysbiosi

2021
Perioperative management and perceived risks of sinus surgery in patients with aspirin-exacerbated respiratory disease.
    International forum of allergy & rhinology, 2021, Volume: 11, Issue:7

    Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Humans; Nasal Polyps; Rhinitis; Sinusitis

2021
Cost-effectiveness analysis comparing dupilumab and aspirin desensitization therapy for chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease.
    International forum of allergy & rhinology, 2021, Volume: 11, Issue:12

    Topics: Antibodies, Monoclonal, Humanized; Aspirin; Chronic Disease; Cost-Benefit Analysis; Desensitization,

2021
Epithelial dysregulation in chronic rhinosinusitis with nasal polyposis (CRSwNP) and aspirin-exacerbated respiratory disease (AERD).
    The Journal of allergy and clinical immunology, 2021, Volume: 148, Issue:5

    Topics: Aspirin; Biomarkers; Chronic Disease; Disease Progression; Disease Susceptibility; Humans; Nasal Pol

2021
Long-term Clinical Outcomes of Aspirin Desensitization With Continuous Daily Aspirin Therapy in Aspirin-exacerbated Respiratory Disease.
    American journal of rhinology & allergy, 2018, Volume: 32, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-In

2018
Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study.
    Respiratory research, 2018, 06-27, Volume: 19, Issue:1

    Topics: Administration, Inhalation; Aspirin; Asthma; Case-Control Studies; Chronic Disease; Cross-Sectional

2018
Differences in urinary leukotriene E4 levels and distribution of eosinophils between chronic rhinosinusitis patients with aspirin-intolerant and-tolerant asthma.
    Nihon Jibiinkoka Gakkai kaiho, 2016, Volume: 119, Issue:12

    Topics: Aspirin; Asthma; Chronic Disease; Drug Tolerance; Eosinophils; Humans; Leukotriene E4; Rhinitis; Sin

2016
A retrospective analysis of esophageal eosinophilia in patients with aspirin-exacerbated respiratory disease.
    The journal of allergy and clinical immunology. In practice, 2019, Volume: 7, Issue:4

    Topics: Aspirin; Asthma, Aspirin-Induced; Cyclooxygenase Inhibitors; Desensitization, Immunologic; Eosinophi

2019
A 1-Day, 90-Minute Aspirin Challenge and Desensitization Protocol in Aspirin-Exacerbated Respiratory Disease.
    The journal of allergy and clinical immunology. In practice, 2019, Volume: 7, Issue:4

    Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Cyclooxygenase Inhibitors; Desensitization, Immun

2019
NSAIDs-hypersensitivity often induces a blended reaction pattern involving multiple organs.
    Scientific reports, 2018, 11-12, Volume: 8, Issue:1

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Drug Hypersensitivity; Female; Huma

2018
Objective and subjective sinonasal and pulmonary outcomes in aspirin desensitization therapy: A prospective cohort study.
    Auris, nasus, larynx, 2019, Volume: 46, Issue:4

    Topics: Aged; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Cohort Studies; Desensitization, Immunologi

2019
[Nasal provocation with increased ASA dose: improved "non-steroidal anti-inflammatory drugs (NSAIDs)-exacerbated disease" (N‑ERD) detection rate in chronic rhinosinusitis patients].
    HNO, 2019, Volume: 67, Issue:8

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Humans;

2019
The bacteriology of chronic rhinosinusitis and the pre-eminence of Staphylococcus aureus in revision patients.
    International forum of allergy & rhinology, 2013, Volume: 3, Issue:8

    Topics: Adult; Aged; Aspirin; Asthma; Chronic Disease; Female; Humans; Male; Middle Aged; Nasal Polyps; Pseu

2013
Non-steroidal anti-inflammatory drug hypersensitivity in adults and the factors associated with asthma.
    Respiratory medicine, 2013, Volume: 107, Issue:7

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Drug Eruptions; Dr

2013
Aspirin sensitivity does not compromise quality-of-life outcomes in patients with Samter's triad.
    The Laryngoscope, 2014, Volume: 124, Issue:1

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chronic Disease;

2014
Nasal lysine aspirin challenge in the diagnosis of aspirin - exacerbated respiratory disease: asthma and rhinitis.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2013, Volume: 43, Issue:8

    Topics: Adult; Aged; Aspirin; Asthma, Aspirin-Induced; Female; Humans; Lysine; Male; Middle Aged; Nasal Prov

2013
Short-term beneficial effect of aspirin in patient with chronic rhinosinusitis and tolerant to acetylsalicylic acid.
    Iranian journal of allergy, asthma, and immunology, 2013, Aug-28, Volume: 12, Issue:4

    Topics: Adult; Aspirin; Chronic Disease; Humans; Male; Rhinitis; Sinusitis

2013
Systemic prednisone administration selectively alters granulocyte subsets in nasal polyps from aspirin-exacerbated respiratory disease and chronic rhinosinusitis patients.
    International forum of allergy & rhinology, 2013, Volume: 3, Issue:11

    Topics: Adult; Aged; Aspirin; Chronic Disease; Ethmoid Sinus; Female; Flow Cytometry; Glucocorticoids; Granu

2013
Aspirin desensitization: useful treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in aspirin-exacerbated respiratory disease (AERD)?
    Current allergy and asthma reports, 2014, Volume: 14, Issue:6

    Topics: Aspirin; Chronic Disease; Desensitization, Immunologic; Drug Hypersensitivity; Drug Tolerance; Human

2014
Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2014, Volume: 151, Issue:4

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitizat

2014
Phenotype of asthma related with high serum periostin levels.
    Allergology international : official journal of the Japanese Society of Allergology, 2015, Volume: 64, Issue:2

    Topics: Adult; Asian People; Aspirin; Asthma; Cell Adhesion Molecules; Cytokines; Drug Tolerance; Eosinophil

2015
Outcomes of complete vs targeted approaches to endoscopic sinus surgery.
    International forum of allergy & rhinology, 2015, Volume: 5, Issue:8

    Topics: Aspirin; Asthma; Chronic Disease; Endoscopy; Female; Humans; Male; Middle Aged; Nasal Polyps; Postop

2015
A conserved linkage group on chromosome 6, the 8.1 ancestral haplotype, is a predisposing factor of chronic rhinosinusitis associated with nasal polyposis in aspirin-sensitive Hungarians.
    Human immunology, 2015, Volume: 76, Issue:11

    Topics: Adolescent; Adult; Aged; Alleles; Aspirin; Case-Control Studies; Chromosomes, Human, Pair 6; Chronic

2015
Clinical Examination of Tissue Eosinophilia in Patients with Chronic Rhinosinusitis and Nasal Polyposis.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2016, Volume: 155, Issue:1

    Topics: Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity; Eosinophilia; Female; Humans; Male; Middle

2016
Olfaction and sinonasal symptoms in patients with CRSwNP and AERD and without AERD: a cross-sectional and longitudinal study.
    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2017, Volume: 274, Issue:3

    Topics: Adult; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Cross-Sectional Studies; Female; Humans; L

2017
Oral corticosteroid prescribing habits for rhinosinusitis: The American Rhinologic Society membership.
    American journal of rhinology & allergy, 2017, Jan-01, Volume: 31, Issue:1

    Topics: Administration, Oral; Adrenal Cortex Hormones; Aspirin; Chronic Disease; Evidence-Based Medicine; Hu

2017
Correlation between the prostaglandin D(2)/E(2) ratio in nasal polyps and the recalcitrant pathophysiology of chronic rhinosinusitis associated with bronchial asthma.
    Allergology international : official journal of the Japanese Society of Allergology, 2008, Volume: 57, Issue:4

    Topics: Adult; Aged; Aspirin; Asthma; Cell Extracts; Chronic Disease; Dinoprostone; Drug Hypersensitivity; E

2008
Otologic manifestations in Samter's syndrome.
    ORL; journal for oto-rhino-laryngology and its related specialties, 2009, Volume: 71, Issue:1

    Topics: Aspirin; Asthma; Chronic Disease; Cohort Studies; Drug Hypersensitivity; Ear Diseases; Ear, Middle;

2009
Proteomics blood testing to distinguish chronic rhinosinusitis subtypes.
    The Laryngoscope, 2008, Volume: 118, Issue:12

    Topics: Aspirin; Asthma; Biomarkers; Chronic Disease; Diagnosis, Differential; Drug Hypersensitivity; Fungi;

2008
Immediate rhinoconjunctivitis induced by metamizole: an allergic reaction?
    Allergy, 2010, Volume: 65, Issue:8

    Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Conjunctivitis, Allergic; Di

2010
[The treatment of polypous suppurative rhinosinusitis in the patients presenting with the severe and moderate aspirin triad].
    Vestnik otorinolaringologii, 2011, Issue:4

    Topics: Aspirin; Asthma; Humans; Nasal Polyps; Rhinitis; Sinusitis; Suppuration

2011
Improvement of chronic rhinitis under aspirin.
    Respiratory care, 2012, Volume: 57, Issue:3

    Topics: Aspirin; Chronic Disease; Cyclooxygenase Inhibitors; Humans; Magnetic Resonance Imaging; Male; Middl

2012
Low SPINK5 expression in chronic rhinosinusitis.
    The Laryngoscope, 2012, Volume: 122, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity;

2012
Incidence of aspirin hypersensitivity in patients with chronic rhinosinusitis and diagnostic value of urinary leukotriene E4.
    Polskie Archiwum Medycyny Wewnetrznej, 2012, Volume: 122, Issue:9

    Topics: Adult; Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity; Female; Humans; Leukotriene E4; Male

2012
A comparative study of eicosanoid concentrations in sputum and urine in patients with aspirin-intolerant asthma.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2002, Volume: 32, Issue:10

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Case-Control Studies; Drug Hypersensitivit

2002
The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2002, Volume: 32, Issue:10

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bronchial Provoca

2002
The natural history and clinical characteristics of aspirin-exacerbated respiratory disease.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2002, Volume: 89, Issue:5

    Topics: Acute Disease; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bronchial Provocatio

2002
[THERAPEUTIC USE OF THE COMBINATION OF CHYMOTRYPSIN WITH ACETYLSALICYLIC ACID IN PEDIATRICS].
    Gazette medicale de France, 1963, Sep-10, Volume: 70

    Topics: Analgesics; Analgesics, Non-Narcotic; Antipyretics; Aspirin; Bronchitis; Child; Chymotrypsin; Fever;

1963
COMPARATIVE EFFECTIVENESS OF THREE ORAL MEDICATIONS IN SINUSTIS AND RHINITIS; A DOUBLE-BLIND STUDY.
    Medical times, 1964, Volume: 92

    Topics: Anti-Allergic Agents; Aspirin; Biomedical Research; Codeine; Double-Blind Method; Headache; Histamin

1964
[VALUE OF CHYMALGYL IN OTORHINOLARYNGOLOGICAL PATHOLOGY. APROPOS OF 20 CASES].
    Gazette medicale de France, 1965, Jan-10, Volume: 72

    Topics: Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antipyretics; Aspirin; Drug Therapy;

1965
Aspirin-sensitive rhinitis-associated changes in upper airway innervation.
    The European respiratory journal, 2003, Volume: 22, Issue:6

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Male; Mid

2003
Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis.
    The Journal of allergy and clinical immunology, 2004, Volume: 113, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Case-Contr

2004
Dynamics of COX-2 in nasal mucosa and nasal polyps from aspirin-tolerant and aspirin-intolerant patients with asthma.
    The Journal of allergy and clinical immunology, 2004, Volume: 114, Issue:4

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Cyclooxygenase 1; Cyclooxygenase 2;

2004
Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis.
    The Journal of allergy and clinical immunology, 2004, Volume: 114, Issue:4

    Topics: Adult; Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity; Enterotoxins; Female; Humans; Immuno

2004
Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis.
    The Journal of allergy and clinical immunology, 2005, Volume: 115, Issue:2

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Epithelial Cells; Fe

2005
Improvements in an oral aspirin challenge protocol for the diagnosis of aspirin hypersensitivity.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2005, Volume: 35, Issue:6

    Topics: Administration, Oral; Adult; Anaphylaxis; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Aspir

2005
Aspirin-triggered 15-HETE generation in peripheral blood leukocytes is a specific and sensitive Aspirin-Sensitive Patients Identification Test (ASPITest).
    Allergy, 2005, Volume: 60, Issue:9

    Topics: Adult; Aged; Aspirin; Asthma; Drug Hypersensitivity; Female; Humans; Hydroxyeicosatetraenoic Acids;

2005
[New pathophysiological concepts on aspirin hypersensitivity (Widal syndrome); diagnostic and therapeutic consequences].
    Bulletin de l'Academie nationale de medecine, 2005, Volume: 189, Issue:6

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chronic Disease; Drug Hypersensitiv

2005
Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells.
    The Journal of allergy and clinical immunology, 2006, Volume: 117, Issue:2

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biopsy; Chronic Disease; Drug Hyperse

2006
Aspirin induced asthma (AIA) with nasal polyps has the highest basal LTE4 excretion: a study vs AIA without polyps, mild topic asthma, and normal controls.
    European annals of allergy and clinical immunology, 2006, Volume: 38, Issue:1

    Topics: Adult; Aspirin; Asthma; Biomarkers; Bronchial Provocation Tests; Humans; Leukotriene E4; Middle Aged

2006
Does it make sense to "desens"? Aspirin desensitization in the treatment of chronic rhinosinusitis.
    Current allergy and asthma reports, 2006, Volume: 6, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chronic Disease; Desensitization, Immunolo

2006
Expression of cyclooxygenase and lipoxygenase enzymes in nasal polyps of aspirin-sensitive and aspirin-tolerant patients.
    Archives of otolaryngology--head & neck surgery, 2006, Volume: 132, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Cyclooxygenase 1; Cyclooxyge

2006
Association between a TGFbeta1 promoter polymorphism and rhinosinusitis in aspirin-intolerant asthmatic patients.
    Respiratory medicine, 2007, Volume: 101, Issue:3

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Drug Hypersensitivity; Female; Gene

2007
Allergy and sinus disease.
    The Medical journal of Australia, 2006, Nov-20, Volume: 185, Issue:10

    Topics: Anti-Allergic Agents; Aspirin; Drug Hypersensitivity; Humans; Nasal Polyps; Respiratory Hypersensiti

2006
Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2007, Volume: 98, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Desensitization, Immunologic; Drug Hyperse

2007
Impact of aspirin intolerance on outcomes of sinus surgery.
    The Laryngoscope, 2007, Volume: 117, Issue:5

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chi-Square Distribution; Chronic Dise

2007
The prevalence of Samter's triad in patients undergoing functional endoscopic sinus surgery.
    Ear, nose, & throat journal, 2007, Volume: 86, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Asthma; Child; Child, Preschool; Chronic Diseas

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
BSACI guidelines for the management of rhinosinusitis and nasal polyposis.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2008, Volume: 38, Issue:2

    Topics: Aspirin; Child; Churg-Strauss Syndrome; Female; Humans; Male; Nasal Polyps; Rhinitis; Sinusitis

2008
Aspirin-sensitive asthma and rhinosinusitis: current concepts and recent advances.
    Ear, nose, & throat journal, 1984, Volume: 63, Issue:2

    Topics: Adult; Aspirin; Asthma; Desensitization, Immunologic; Drug Tolerance; Humans; Rhinitis; Sinusitis

1984
[Bronchial asthma, nasal polyposis and analgesic intolerance (the ASA triad). A successful computer based analysis of free texts].
    Schweizerische medizinische Wochenschrift, 1984, Mar-10, Volume: 114, Issue:10

    Topics: Analgesics; Aspirin; Asthma; Chronic Disease; Computers; Drug Tolerance; Humans; Nasal Polyps; Rhini

1984
[Rhinosinusitis polyposa and intolerance to analgesics (aspirin intolerance)].
    Laryngologie, Rhinologie, Otologie, 1983, Volume: 62, Issue:3

    Topics: Adult; Aged; Analgesics; Aspirin; Bronchial Provocation Tests; Drug Hypersensitivity; Drug Tolerance

1983
Aspirin intolerance presenting as chronic rhinitis.
    Rhode Island medical journal, 1980, Volume: 63, Issue:3

    Topics: Aspirin; Chronic Disease; Diagnosis, Differential; Drug Hypersensitivity; Eosinophilia; Female; Head

1980
Aspirin-induced asthma in children.
    Annals of allergy, 1982, Volume: 48, Issue:1

    Topics: Acetylation; Adolescent; Anti-Inflammatory Agents; Aspirin; Asthma; Child; Complement System Protein

1982
Evaluation of intolerance to analgesics, preservatives and food colorants with challenge tests.
    European journal of respiratory diseases, 1982, Volume: 63, Issue:5

    Topics: Adolescent; Adult; Aged; Aspirin; Asthma; Bronchial Provocation Tests; Child; False Negative Reactio

1982
[Broncaspin in the therapy of pediatric diseases of the respiratory tract].
    Minerva medica, 1981, Feb-28, Volume: 72, Issue:7

    Topics: Age Factors; Anti-Bacterial Agents; Aspirin; Bronchitis; Bronchopneumonia; Child; Child, Preschool;

1981
Nasal secretions in response to acetylsalicylic acid.
    The Journal of allergy and clinical immunology, 1993, Volume: 91, Issue:2

    Topics: Adult; Aged; Aspirin; Asthma; Drug Hypersensitivity; Female; Humans; Inflammation; Male; Middle Aged

1993
Medical management of sinusitis.
    The American journal of the medical sciences, 1998, Volume: 316, Issue:1

    Topics: Adrenal Cortex Hormones; Aspirin; Drainage; Humans; Hypersensitivity; Nasal Decongestants; Nasal Sep

1998
[A case of aspirin triad].
    Vestnik otorinolaringologii, 1999, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Drug Hypersensitivity; Follow-Up

1999
NSAID-induced bronchospasm--a common and serious problem. A report from MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority.
    The New Zealand dental journal, 1999, Volume: 95, Issue:421

    Topics: Adult; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bronchial Spasm; Chroni

1999
Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: evaluation of nasal response by acoustic rhinometry.
    Thorax, 2000, Volume: 55, Issue:11

    Topics: Administration, Intranasal; Adult; Aged; Aspirin; Asthma; Cyclooxygenase Inhibitors; Female; Humans;

2000
[Family study of patients with aspirin intolerance and rhinosinusitis].
    HNO, 2000, Volume: 48, Issue:9

    Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bronchial Provocation T

2000
Individual monitoring of aspirin desensitization.
    Archives of otolaryngology--head & neck surgery, 2001, Volume: 127, Issue:3

    Topics: Adult; Aged; Aspirin; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Male; Mid

2001
Aspirin desensitization for chronic hyperplastic sinusitis, nasal polyposis, and asthma triad.
    Archives of otolaryngology--head & neck surgery, 2001, Volume: 127, Issue:10

    Topics: Adult; Aged; Aspirin; Asthma; Chronic Disease; Desensitization, Immunologic; Drug Hypersensitivity;

2001
Decreased apoptosis and distinct profile of infiltrating cells in the nasal polyps of patients with aspirin hypersensitivity.
    Allergy, 2002, Volume: 57, Issue:6

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antigens, CD; Antigens, Differentiation, Myelo

2002
Rhinitis medicamentosa.
    The Western journal of medicine, 1979, Volume: 131, Issue:4

    Topics: Antihypertensive Agents; Aspirin; Cocaine; Drug-Related Side Effects and Adverse Reactions; Estrogen

1979
Aspirin idiosyncrasy.
    Journal of the American Dental Association (1939), 1979, Volume: 98, Issue:5

    Topics: Aspirin; Asthma; Drug Hypersensitivity; Humans; Male; Middle Aged; Nasal Polyps; Rhinitis

1979
Hypersensitivity to nonsteroidal antiinflammatory drugs: indications and methods for oral challenges.
    The Journal of allergy and clinical immunology, 1979, Volume: 64, Issue:6 pt 2

    Topics: Anti-Inflammatory Agents; Aspirin; Asthma; Bronchial Provocation Tests; Drug Hypersensitivity; Human

1979
Aspirin intolerance in asthmatic patients: case histories.
    Annals of allergy, 1977, Volume: 38, Issue:4

    Topics: Adult; Aspirin; Asthma; Female; Humans; Rhinitis; Sinusitis

1977
Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients.
    British medical journal, 1975, Jan-11, Volume: 1, Issue:5949

    Topics: Adult; Aged; Analgesics; Aspirin; Asthma; Bronchi; Drug Hypersensitivity; Female; Flufenamic Acid; H

1975
Intolerance to aspirin.
    American family physician, 1975, Volume: 12, Issue:5

    Topics: Aspirin; Asthma; Drug Hypersensitivity; Humans; Nasal Polyps; Rhinitis

1975
Tryptase and histamine release during aspirin-induced respiratory reactions.
    The Journal of allergy and clinical immunology, 1991, Volume: 88, Issue:6

    Topics: Administration, Oral; Adult; Aspirin; Asthma; Forced Expiratory Volume; Histamine; Histamine Release

1991
Inhalation and nasal challenge in the diagnosis of aspirin-induced asthma.
    Allergy, 1991, Volume: 46, Issue:6

    Topics: Adult; Aged; Aspirin; Asthma; Bronchial Provocation Tests; Female; Forced Expiratory Volume; Humans;

1991
Long-term effects of aspirin desensitization--treatment for aspirin-sensitive rhinosinusitis-asthma.
    The Journal of allergy and clinical immunology, 1990, Volume: 85, Issue:1 Pt 1

    Topics: Adrenal Cortex Hormones; Adult; Aspirin; Asthma; Combined Modality Therapy; Desensitization, Immunol

1990
Nonallergic rhinitis with eosinophilia syndrome a precursor of the triad: nasal polyposis, intrinsic asthma, and intolerance to aspirin.
    Annals of allergy, 1990, Volume: 64, Issue:6

    Topics: Adolescent; Adult; Aspirin; Asthma; Child; Drug Tolerance; Eosinophilia; Female; Humans; Male; Middl

1990
[NARES syndrome. A developing link in the Fernand-Widal triad].
    Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Societe d'oto-laryngologie des hopitaux de Paris, 1989, Volume: 106, Issue:1

    Topics: Adult; Aspirin; Asthma; Autonomic Nervous System Diseases; Eosinophilia; Female; Humans; Male; Middl

1989
[Clinical aspect of aspirin-induced asthma].
    Nihon Jibiinkoka Gakkai kaiho, 1985, Volume: 88, Issue:7

    Topics: Adult; Aspirin; Asthma; Drug Hypersensitivity; Female; Humans; Male; Middle Aged; Nasal Polyps; Para

1985
[Diagnostic and therapeutic methods in the asthmatic triad].
    Terapevticheskii arkhiv, 1985, Volume: 57, Issue:11

    Topics: Adolescent; Adult; Aspirin; Asthma; Bronchial Provocation Tests; Child; Desensitization, Immunologic

1985
Rhinitis medicamentosa.
    Annals of allergy, 1968, Volume: 26, Issue:8

    Topics: Aspirin; Cocaine; Drug Hypersensitivity; Ephedrine; Epinephrine; Estrogens; Humans; Iodides; Ipecac;

1968
Familial occurrence of asthma, nasal polyps and aspirin intolerance.
    Annals of internal medicine, 1973, Volume: 78, Issue:1

    Topics: Adult; Aspirin; Asthma; Diseases in Twins; Drug Hypersensitivity; Environment; Female; Genotype; Hum

1973
[Aspirin intolerance in a child].
    L'union medicale du Canada, 1973, Volume: 102, Issue:3

    Topics: Adolescent; Aspirin; Asthma; Bronchodilator Agents; Child; Drug Hypersensitivity; Fever; Humans; Mal

1973
Urticaria induced by preservatives and dye additives in food and drugs.
    The British journal of dermatology, 1973, Volume: 88, Issue:6

    Topics: Angioedema; Aspirin; Azo Compounds; Benzoates; Coloring Agents; Drug Hypersensitivity; Erythema; Foo

1973
Aspirin and other cross-reacting small chemicals in known aspirin intolerant patients.
    Annals of allergy, 1973, Volume: 31, Issue:10

    Topics: Analgesics; Antioxidants; Aspirin; Asthma; Blood Coagulation; Cross Reactions; Dose-Response Relatio

1973
Tween 80 exacerbated intrinsic rhinitis and asthma in non-aspirin-sensitive patients.
    Annals of allergy, 1974, Volume: 32, Issue:6

    Topics: Aspirin; Asthma; Blood Vessels; Chemical Phenomena; Chemistry; Cholestyramine Resin; Diabetes Compli

1974
Concerning the nature of intolerance to aspirin.
    The Journal of allergy, 1967, Volume: 40, Issue:5

    Topics: Aminopyrine; Antipyrine; Aspirin; Asthma; Chemoreceptor Cells; Drug Hypersensitivity; Edema; Histami

1967
Acetylation of human serum albumin by acetylsalicylic acid.
    Science (New York, N.Y.), 1968, May-17, Volume: 160, Issue:3829

    Topics: Acetates; Acetrizoic Acid; Alkylation; Animals; Aspirin; Asthma; Autoradiography; Carbon Isotopes; C

1968